The roles of nitric oxide synthases (NOS) in endochondral bone formation by Yan, Qian
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
September 2010 
The roles of nitric oxide synthases (NOS) in endochondral bone 
formation 
Qian Yan 
The University of Western Ontario 
Supervisor 
Dr. Frank Beier 
The University of Western Ontario 
Graduate Program in Physiology 
A thesis submitted in partial fulfillment of the requirements for the degree in Doctor of 
Philosophy 
© Qian Yan 2010 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Cell Biology Commons, Cellular and Molecular Physiology Commons, and the 
Developmental Biology Commons 
Recommended Citation 
Yan, Qian, "The roles of nitric oxide synthases (NOS) in endochondral bone formation" (2010). Electronic 
Thesis and Dissertation Repository. 15. 
https://ir.lib.uwo.ca/etd/15 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
THE ROLES OF NITRIC OXIDE SYNTHASES (NOS) IN 
ENDOCHONDRAL BONE FORMATION 
 
 
(Spine Title: NOS in endochondral bone formation) 
(Thesis Format: Integrated Article) 
 
 
By 
 
Qian  Yan 
 
 
Graduate Program in Physiology 
 
 
A thesis submitted in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
 
 
School of Graduate and Postdoctoral Studies 
The University of Western Ontario 
London, Ontario, Canada 
 
 
© Qian Yan, 2010 
 
 
 
 
ii 
THE UNIVERSITY OF WESTERN ONTARIO 
FACULTY OF GRADUATE AND POSTDOCTORAL STUDIES 
 
 
CERTIFICATE OF EXAMINATION 
 
 
Supervisor 
 
_______________________________  
 
Dr. Frank Beier  
 
 
Supervisory Committee 
 
______________________________  
Dr. Jane Rylett (GSR) 
 
 
______________________________  
Dr. Moshmi Bhattacharya  
 
 
______________________________ 
Dr. Qingping Feng 
Examiners 
 
______________________________  
Dr. Thomas Drysdale  
(Department) 
 
 
______________________________  
Dr. Peter Chidiac 
(Department) 
 
 
______________________________ 
Dr. Chandan Chakraborty 
(University) 
 
 
_____________________________  
Dr. Cristina Teixeira New York University 
(External) 
 
 
The thesis by 
 
Qian Yan 
 
entitled: 
 
The Roles of Nitric Oxide Synthases (NOS) in Endochondral Bone Formation 
 
is accepted in partial fulfillment of the  
requirements for the degree of  
Doctor of Philosophy 
  
 
 
Date____________________ _______________________________ 
Chair of the Thesis Examination Board 
 
 
iii 
ABSTRACT 
 
Longitudinal growth of endochondral bones is controlled by the cartilage growth 
plate. Chondrocyte proliferation and hypertrophy, vascular invasion, formation of 
ossification centers and cartilage replacement by bone tissue are all important processes 
required for normal growth. These biological processes have to be tightly regulated or 
disturbances will lead to skeletal diseases. A large number of genes, growth factors and 
hormones have been implicated in the regulation of growth plate biology, however, less 
is known about the intracellular signaling pathways involved. Nitric oxide (NO) has been 
identified as a regulator of cellular proliferation, differentiation, migration, survival and 
metabolism in multiple cell types. In bone biology, it has been implicated in bone 
remodeling and the pathogenesis of osteoarthritis, but the roles of specific nitric oxide 
synthase (NOS) enzymes in chondrocyte physiology and cartilage development are 
unclear. The goal of this thesis was to analyze the roles of NOS/NO signaling in specific 
stages of endochondral bone formation.  
            We had shown recently that chondrocyte-specific deletion of the Rac1 gene 
results in severe dwarfism due to reduced chondrocyte proliferation in mice, but the 
molecular pathways involved remained unknown. Employing a Rac1-deficient 
monolayer chondrocyte culture, we showed that loss of Rac1 results in severely reduced 
levels of inducible nitric oxide synthase (iNOS) protein and NO production. Additionally, 
reduced iNOS expression was found in Rac1-decifient mice in vivo. Using a tibia organ 
culture system, we showed that NO donors rescued the antiproliferative effects of Rac1 
inhibition.  Examination of the growth plate of iNOS-deficient mice revealed reduced 
chondrocyte proliferation and decreased expression of cyclin D1, while ATF3, a 
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suppressor of cyclin D1 transcription, showed increased expression. Thus, we identified 
iNOS/NO as a novel mediator of Rac1 signaling and ATF3 as a link between iNOS and 
chondrocyte cell cycle.   
          Doe to the skeletal phenotypes we observed in iNOS-deficient mice, my next study 
investigated effects of inactivation of endothelial nitric oxide synthase (eNOS) on 
cartilage development in mice. eNOS-deficient mice showed increased lethality and 
reduced bone growth, delayed ossification and a marked reduction in the number of 
proliferating chondrocytes. The mechanisms leading to these bone phenotypes appear to 
be caused by decreased cyclin D1 and increased p57 expressions in mutants, resulting in 
slower cell cycle progression and earlier cell cycle exit. Additionally, expression of early 
chondrocyte markers such as Sox9 was reduced and prehypertrophic markers were 
upregulated in mutant mice.  
           Because my studies had shown upregulation of nNOS in eNOS-null cartilage, next 
I analyzed the skeletal phenotype of nNOS-deficient mice. Transient growth retardation, 
reduced length of long bones, less trabecular bone and decreased mineralization were 
shown in nNOS KO mice. Reduced proliferating chondrocyte numbers in mutants may in 
part be due to premature cell cycle exit, shown by reduced cyclin D1 and upregulated p57 
expressions. Similar to the other two mutant strains, ATF3 was a link between nNOS and 
reduced cyclin D1 expression. In addition, I demonstrated increased apoptosis, reduced 
early chondrocyte markers such as Sox genes and increased prehypertrophic markers 
RORα and c-Fos in mutant mice. Together, these data suggest that NOS/NO presents a 
core signaling pathway to regulate chondrocyte proliferation and differentiation through 
control of cell cycle protein. 
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CHAPTER ONE 
 
INTRODUCTION AND LITERATURE REVIEW 
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1.1 Introduction 
1.1.1 The function of bones 
         The skeletal system is one of the major organ systems in the human body and made 
up of 206 bones (Docherty, 2007a). The most obvious and one of the most important 
skeletal functions is to provide a framework that supports the human body and protects 
internal organs such as brain, spinal cord, heart, lungs, liver, and kidneys. There are also 
many other functions of the skeletal system that are essential for other processes in the 
human body. The bones in our body are joined and facilitate muscle contractions to move 
and perform our daily work.  The skeleton is also a regulator of metabolism and acts as a 
reservoir of minerals such as calcium and phosphorous (Karsenty et al., 2009). 
Additionally, bone marrow is a place for hematopoiesis, where the formation of new 
blood cells takes place. 
1.1.2 The organization of the human skeletal system 
         The human skeletal system is perpendicularly symmetrical in nature. It consists of 
the axial and the appendicular skeletons. The axial skeleton includes bones of the 
vertebral column, thoracic and rib cages, sternum and skull. It is made up of 80 bones 
(Docherty, 2007b). The main function of the axial skeleton is the protection of organs, 
like heart, brain and lungs, and maintaining the upright position of the body. The 
appendicular skeleton is attached to the axial skeleton, including pectoral girdles 
(shoulder portion), upper limbs, pelvic girdle (hip portion) and lower limbs. Body 
movements are possible because of these bones (Docherty, 2007b).  
 
 
3 
 
1.1.3 Skeletogenesis   
        The process by which bones are formed is called ossification. Ossification is an 
extremely complex, life-long process (Docherty, 2007a). Formation of the adult skeleton 
is achieved through two independent mechanisms: intramembranous and endochondral 
ossification (Beier, 2005; Olsen et al., 2000). In intramembranous bone formation, 
mesenchymal cells directly differentiate into osteoblasts. Some of the craniofacial bones 
are formed this way. Endochondral ossification (EO) is the process responsible for 
formation of the majority of bones in the vertebrate skeleton (Teixeira et al., 2008; 
Wagner and Karsenty, 2001). EO starts from mesenchymal cells that condense at the 
position of future bone, through a complex process of chondrogenesis to form a highly 
controlled and precisely shaped cartilage template (Ballock and O'Keefe, 2003). The 
cartilage template grows through chondrocyte proliferation and differentiation to 
establish the cartilage growth plate that ultimately drives the longitudinal growth of the 
bone. This process eventually determines the adult height (Fig. 1.1).  Long bones such as 
femur are formed through this process. Finally, a process of growth and remodeling after 
birth (in a growth and maintenance phase) results in a skeleton which is well adapted to 
its function as an organ not only for support and protection of internal organs, but also for 
movement , blood cell formation and regulation of calcium homeostasis. 
 
1.2 Endochondral bone formation 
1.2.1 Chondrogenesis 
         Endochondral ossification is initiated by aggregation of mesenchymal cells, 
followed by cell differentiation into chondrocytes through the process of chondrogenesis. 
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Figure 1.1 Overview of endochondral ossification. 
During embryogenesis, mesenchymal cells start to aggregate and condense at the location 
of future bone. They then differentiate into chondrocyte in the center of these 
condensations through chondrogenesis.  Chondrocytes proliferate and differentiate within 
these condensations leading to the formation of cartilage anlagen.  At the periphery of the 
condensations, cells flatten, elongate and form the perichondrium. These chondrocytes 
also keep proliferating to expand the cartilage template. Eventually, cells at the center of 
this template terminally differentiate into hypertrophic cells. Perichondral cells adjacent 
to hypertrophic chondrocyte become osteoblasts, forming a bone collar. Hypertrophic 
chondrocyte direct mineralization of the surrounding cartilage matrix, attract blood vessel 
invasion, and then undergo apoptosis. Osteoblasts form early trabecular bone adjacent to 
the hypertrophic chondrocytes, forming the primary spongiosa. Epiphyseal growth plates 
form at the both ends of the long bone with unique organization of the chondrocytes.  At 
the end of the bone, the secondary ossification center forms through cycles of 
chondrocyte hypertrophy, vascular invasion and osteoblast activity.  
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Chondrogenesis is a highly complex process leading to the formation of a cartilage 
template (Provot and Schipani, 2005). Early condensations can be found in the human 
fetus at 6.5 week of gestation and at 10.5 days (E10.5) of embryonic mouse development 
(Kaufman, 1992). At this time point in development, the shape, number and position of 
future skeletal elements are decided (Goldring et al., 2006). Members of the Sox family 
of transcription factors (Sox9, Sox5 and Sox6) are required for this early differentiation 
(Wagner and Karsenty, 2001). Sox9 is one of the earliest markers expressed in cells 
undergoing condensation. Sox9 transcript is detected in all prechondrogenic 
mesenchymal condensation as early as 8.5-9.5 days of mouse embryonic development 
(Kaufman, 1992), and the expression peaks in cartilage at E11.5-14.5 days (Asou et al., 
2002). Sox5 and 6 are not found in condensations, but they are co-expressed with Sox9 
during differentiation (Wagner and Karsenty, 2001). Cells in the condensations 
differentiate to chondrocytes and deposit an extracellular matrix specific for cartilage, 
consisting of molecules such as collagens II, IX, and XI and proteoglycans (e.g. 
aggrecan). At the border of the condensations, chondrocytes differentiate to flattened 
elongated cells to form the perichondrium (Kronenberg, 2003).  All these events 
contribute to the establishment of cartilage anlagen for the future bone elements (Fig. 
1.1).  Cartilage anlagen can be observed at 7 weeks of human and 11.5 days of mouse 
embryonic development (Olsen et al., 2000; Kaufman, 1992). 
1.2.2 Epiphyseal growth plate 
         Once mesenchymal cells commit to the chondrogenic lineage, the subsequent 
events of EO occur through the epiphyseal growth plate. Longitudinal bone growth 
dictates the final height of human bodies and is dependent on the activity of the growth 
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plates (Provot and Schipani, 2005). The growth plate is established around the end of the 
first trimester in human fetal development and around embryonic day 15 in mice 
(Kaufman, 1992). The growth plate is a unique structure where specific chondrocyte 
populations are organized in distinct zones (e.g. zones of resting, proliferating, and 
hypertrophic chondrocytes) based on their morphology, cellular activities and gene 
expression patterns (Ballock and O'Keefe, 2003) (Fig. 1.1).  Within these zones, the 
chondrocytes are organized in distinguishable columnar arrays and express different 
matrix proteins (Olsen et al., 2000).  
           The resting chondrocytes are small round cells in a relatively quiescent state and 
located furthest away from the primary ossification center. It is believed that some of 
these cells have stem-like properties, and can give rise to the neighboring proliferative 
zone (Ballock and O'Keefe, 2003). Within this zone of the growth plate, flattened 
proliferating chondrocytes are organized in a columnar array, and proliferation of 
chondrocytes occurs in a unidirectional manner, resulting in longitudinal growth of the 
bone (Hunziker, 1994). Both resting and proliferating chondrocytes express extracellular 
matrix (ECM) molecules, such as collagen II and aggrecan (Kronenberg, 2003). 
Throughout chondrogenesis, the balance of signaling by growth factors such as bone 
morphogenetic proteins (BMPs) and fibroblast growth factors (FGFs) determines the rate 
of proliferation (Hoffmann and Gross, 2001). Chondrocyte proliferation is also under 
control of cell-cycle proteins, such as cyclin D1 and A (Beier, 2005; Karsenty and 
Wagner, 2002; Kronenberg, 2003).  
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1.2.3 Chondrocyte hypertrophy and extracellular matrix production 
         Chondrocytes in the center of the cartilage mould then stop proliferating, start to 
differentiate into prehypertrophic cells, and eventually enlarge to terminally differentiated 
hypertrophic chondrocytes under the control of several cell cycle genes and different 
transcription factors (Colnot, 2005; Karsenty and Wagner, 2002; Kronenberg, 2003). The 
transcription factor RUNX2 (runt related transcript factor 2) is required for this terminal 
chondrocyte differentiation (Olsen et al., 2000; Provot and Schipani, 2005). It has been 
shown that chondrocyte hypertrophy is responsible for 60% of long bone growth, and the 
rest is due to both matrix synthesis and chondrocyte proliferation (Hunziker, 1994; 
Hunziker and Schenk, 1989; Nilsson et al., 1994).  
          Hypertrophic chondrocytes are the principle regulators of the subsequent events of 
bone growth (Karsenty and Wagner, 2002; van der Eerden et al., 2003). They change 
their gene expression pattern to synthesize type X collagen, direct the mineralization of 
their extracellullar matrix, attract blood vessel invasion through the production of 
vascular endothelial growth factor (VEGF), activate osteoclasts to digest the matrix, and 
direct adjacent perichondral cells to become osteoblasts, which then secret a matrix rich 
in type I collagen and form a bone collar around the center of the cartilage template 
(Goldring et al., 2006; Kronenberg, 2003) (Fig. 1.1). Hypertrophic chondrocytes then 
undergo apoptotic cell death (Shum and Nuckolls, 2002). The cartilage matrix provides a 
scaffold for osteoblasts to lay down bone matrix within it (Ballock and O'Keefe, 2003; 
Kronenberg, 2003; Lefebvre and Smits, 2005; Lotz et al., 1999; Olsen et al., 2000).  
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1.2.4 Blood vessel invasion and ossification centers 
         VEGF and other angiogenic factors secreted by hypertrophic chondrocytes recruit 
endothelial cells from the surrounding blood circulation, and trigger vascular invasion 
from the periosteum (once vascularized, the perichondrium becomes the periosteum) 
(Hunziker, 1994). This invasion brings osteoclasts and hematopoietic cells into the 
mineralized cartilage. The newly recruited osteoclasts start to degrade the mineralized 
matrix (Drissi et al., 2005; Hunziker, 1994). Osteoblasts are also recruited from the 
periosteum, and lay down a new bone-specific matrix on the remains of the hypertrophic 
cartilaginous matrix. With the formation of the early trabecular bone, the primary 
spongiosa is established from the middle of the growth plates and eventually develops 
into a primary ossification center (POC) (Fig. 1.1). Another step in endochondral bone 
formation is the formation of secondary ossification centers (SOCs), which initiate at a 
late stage of the development. They start to appear at postnatal day 5 or 6 in mice (Olsen 
et al., 2000; van der Eerden et al., 2003). These centers form in the middle of epiphyseal 
cartilage after establishment of the growth plates. After formation of the secondary 
ossification center, the epiphyseal cartilage is now separated from the growth plate by the 
SOC and will eventually develop into articular cartilage at the far end of bone, which 
provides an important cushion during the whole adult life (Hunziker and Schenk, 1989) 
(Fig. 1.2). The longitudinal growth of the bone continues to depend on the activity of the 
epiphyseal growth plates between primary and secondary ossification centers (Ballock 
and O'Keefe, 2003). In humans, it closes during puberty (when primary and secondary 
ossification centers fuse) and eventually determines adult height (Shum and Nuckolls, 
2002).   
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Figure 1.2 The formation of secondary ossification centers.  
The secondary ossification centers (SOC) form in the middle of the epiphyseal cartilage 
after establishment of growth plates. At this point, the epiphyseal cartilage that is now 
separated from the growth plate by the SOC will eventually develop into articular 
cartilage at the far end of bone, which provides an important cushion during the whole 
adult life. The longitudinal growth of the bone continues to depend on the activity of the 
epiphyseal growth plates between primary and secondary ossification centers. In humans, 
the growth plates close during puberty and eventually determine adult height.  The 
mechanisms leading to the formation of the secondary ossification centers are similar to 
the formation of primary ossification centers. (POC: primary ossification center). 
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        The mechanisms leading to the formation of the secondary ossification centers are 
similar to the formation of primary ossification centers. The formation of secondary 
ossification centers is delayed in cartilage disease, such as spondyloepiphyseal dysplasia 
(Zelzer and Olsen, 2003).  
1.2.5 Bone modeling and remodeling 
         The last step in bone development is the tissue modeling and remodeling. Bone 
tissues experience consistent modeling and remodeling during development and in adult 
life, through the coordinated activity of bone-forming osteoblasts and bone-resorbing 
osteoclasts (Docherty, 2007a; Karsenty and Wagner, 2002; Olsen et al., 2000; Ortega et 
al., 2004).  Cytokines released from bone resorption by osteoclasts activate osteoblast 
precursors to lay down cyclically shaped osteoid that is then mineralized to form new 
osteon (Holmbeck and Szabova, 2006; Olsen et al., 2000). Communication between 
bone-forming osteoblasts, bone-resorbing osteoclasts and other bone cells regulates bone 
turnover in balancing the normal remodeling sequence under control of local and 
systemic bone remodeling pathways (Holmbeck and Szabova, 2006).  
 
1.3 Systemic control and local regulators of longitudinal growth  
1.3.1 Endocrine factors  
         The process of longitudinal bone growth is governed by a complex network of 
endocrine signals, including growth hormone, insulin-like growth factor I, 
glucocorticoids, thyroid hormone, estrogen, androgen, vitamin D, and leptin (Nilsson et 
al., 2005). Many of these signals regulate growth plate function, both by acting locally on 
growth plate chondrocytes and indirectly by modulating other endocrine signals in the 
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network (Nilsson et al., 1994). Some of the local effects of hormones are mediated by 
changes in paracrine factors that control chondrocyte proliferation and differentiation 
(Nilsson et al., 1994). Many human skeletal growth disorders are caused by abnormalities 
in the endocrine regulation of the growth plate (Nilsson et al., 1994; van der Eerden et al., 
2003; Zelzer and Olsen, 2003), some of which are discussed below. 
1.3.1.1 Growth Hormone (GH) and insulin-like growth factors (Igfs) 
           GH is a peptide hormone secreted by the pituitary gland that stimulates growth and 
cell reproduction. Igfs are peptide hormones secreted from many different cells (Nilsson 
et al., 2005). GH and Igfs are potent stimulators of longitudinal bone growth (Mushtaq et 
al., 2004). GH excess, due to pituitary adenomas in childhood, results in gigantism. 
Conversely, GH deficiency or insensitivity due to GH-receptor mutations or defects in 
GH signaling pathways markedly impairs postnatal growth (Osafo et al., 2005). Mice 
lacking the GH gene exhibit normal birth weight, but a reduction in postnatal growth 
(Osafo et al., 2005). Mice lacking either the Igf-1 or Igf-2 genes show intrauterine growth 
retardation with birth weights approximately 60% that of wild-type littermates (Wang et 
al., 2006). The original somatomedin hypothesis stipulates that the effects of GH on 
linear growth are mediated by stimulating Igf-1 expression, including in chondrocytes 
(Hunziker, 1994; Nilsson et al., 1994; Nilsson et al., 2005).  
1.3.1.2 Glucocorticoids 
           Glucocorticoids are widely used as anti-inflammatory and immunosuppressive 
drugs in children (Silvestrini et al., 2000). Long-term, high-dose glucocorticoid treatment 
often leads to growth failure and osteoporosis (Silvestrini et al., 2000). Similarly, 
systemic administration of glucocorticoids in mice, rats, and rabbits decreases the rate of 
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longitudinal bone growth, by inhibiting growth plate chondrocyte proliferation 
(Silvestrini et al., 2000). In addition, glucocorticoids may stimulate apoptosis of growth 
plate chondrocytes (Nilsson et al., 1994). The local effects of glucocorticoids on growth 
plate chondrocyte proliferation may be mediated, in part, by changes in the local Igf-I 
system (Nilsson et al., 2005; Silvestrini et al., 2000).  
1.3.1.3 Thyroid hormone 
           The thyroid hormones, thyroxine (T4) and triiodothyronine (T3), are tyrosine-
based hormones produced by the thyroid gland and primarily responsible for regulation 
of metabolism. Thyroid hormone is necessary for normal skeletal growth and maturation 
(Stevens et al., 2000). Hypothyroidism slows longitudinal bone growth and endochondral 
ossification, while hyperthyroidism accelerates both processes (Nilsson et al., 1994). In 
hypothyroid animals, there is a decrease in the heights of the proliferative and 
hypertrophic zones, and a decrease in chondrocyte proliferation, hypertrophy, and 
vascular/bone cell invasion (Stevens et al., 2000). Additionally, the normal columnar 
organization of the growth plate is disrupted (Stevens et al., 2000). Some of the skeletal 
effects of thyroid hormone appear to be due to a direct action on the growth plate 
(Nilsson et al., 1994). 
1.3.2 Local regulatory mechanisms in the growth plate 
         Proliferation and hypertrophy of growth plate chondrocytes and ECM production 
drive the longitudinal growth of endochondral bones and eventually determine body 
length in mammals (Beier, 2005; Kronenberg, 2003; Okazaki and Iwamoto, 2006). Many 
growth factors and transcription factors control these processes. Bone morphogenetic 
proteins (BMPs) and the central transcription factor Sox 9 regulate early chondrocyte 
15 
 
differentiation (Beier, 2005; Karsenty and Wagner, 2002). Chondrocyte proliferation is 
under control of Indian hedgehog (Ihh),  parathyroid hormone-related protein (PTHrP) 
and Fibroblast growth factor (FGF) signaling, and cell-cycle genes, such as Cyclin D1 
and A (Beier, 2005; Kronenberg, 2003). Eventually, chondrocytes differentiate to mature 
hypertrophic cells under control of the transcription factor RUNX2 among others 
(Karsenty and Wagner, 2002; Kronenberg, 2003; Shum and Nuckolls, 2002) (Fig. 1.3).  
VEGF and RANKL mediate angiogenesis and osteoclast activation respectively along 
with other growth factors (Olsen et al., 2000). Other local factors include transforming 
growth factor β, and Wnt families (Beier, 2005; Nilsson et al., 2005; Olsen et al., 2000; 
Teixeira et al., 2008).  
1.3.2.1 The Ihh/PTHrP negative feed-back loop 
           Ihh is a master regulator of bone development, coordinating chondrocyte 
proliferation, chondrocyte differentiation and osteoblast differentiation (Kronenberg, 
2003). During endochondral ossification, Ihh is synthesized by prehypertrophic and early 
hypertrophic chondrocytes within the growth plates. It binds to its receptor Patched-1 
(Ptc-1), causing activation of Smoothened (Smo), which then triggers a cascade leading 
to gene activation (Kronenberg, 2003; Wagner and Karsenty, 2001). PTHrP is secreted 
from perichondral cells and resting chondrocytes at the ends of long bone. It acts on 
receptors on proliferating chondrocytes to keep them in the proliferative pool (Nilsson et 
al., 2005).  The interaction of Ihh and PTHrP leads to the hypothesis that these two 
paracrine factors together control the number of chondrocytes in the proliferative pool 
through a feed-back loop (Karp et al., 2000; Kronenberg, 2003). When chondrocytes 
close to the hypertrophic zone are no longer sufficiently stimulated by PTHrP, they stop  
16 
 
 
 
 
 
 
 
Figure 1.3 Local regulators of growth plate and life cycle of chondrocyte. 
Longitudinal growth of the cartilage growth plate is under control of many secreted 
factors and endogenous regulators such as transcription factors. Each stage of 
chondrocyte  is characterized by express specific molecular markers and matrix proteins 
(in red): the aggregates of mesenchymal cells express BMPs and Sox family proteins; 
resting cells express Sox proteins, PTH/PTHrP, FGFR2 and collagen II; proliferative 
chondrocytes express FGFR3, cell cycle proteins such as Cyclins D1 and A, and collagen 
II and aggrecan;  prehypertrophic cells are under control of the transcription factor 
RUNX2, and express Ihh and FGFs; hypertrophic cells express collagen X, MMP13 and 
ALP in bone matrix.  
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proliferating and start to synthesize Ihh. Ihh then acts on its receptor on chondrocyte to 
increase the rate of proliferation and also stimulates the production of PTHrP at the ends 
of growth plates through an unknown mechanism (Wagner and Karsenty, 2001). Ihh also 
acts on perichondrial cells to convert these cells into osteoblasts of the bone collar (Karp 
et al., 2000).  
1.3.2.2 Opposing actions of BMPs and FGFs 
           FGFs are secreted proteins that act through tyrosine kinase receptors. The FGF 
family of proteins consists of at least 23 structurally related polypeptides that play a 
critical role in a variety of biological processes. FGF1, 2, 4, 8, 9, and particularly 18 
(Provot and Schipani, 2005), and their four receptors are expressed during endochondral 
bone formation (Ornitz and Marie, 2002). It has been shown that FGF signaling regulates 
chondrocyte proliferation and differentiation (Karsenty and Wagner, 2002; Kronenberg, 
2003; Ornitz and Marie, 2002).  FGF receptor 3 (FGFR3) is expressed in proliferating 
chondrocytes; FGFR1 is expressed in prehypertrophic and hypertrophic chondrocytes and 
perichondrium; and FGFR2 is expressed in the perichondrium and primary spongiosa 
(Kronenberg, 2003). FGF18 is expressed in the perichondrium, and acts on FGFR 3 to 
decrease chondrocyte proliferation, to increase the production of Ihh, and to accelerate 
the differentiation of hypertrophic chondrocyte into terminal differentiated chondrocytes 
(Ornitz and Marie, 2002).  BMPs are members of the TGF-β family of paracrine factors, 
which have essential roles at every stage of endochondral bone development (Hoffmann 
and Gross, 2001). They act on each of these steps, sometimes in a manner opposite to the 
effects of FGFs (Kronenberg, 2003).  They accelerate chondrocyte proliferation, increase 
Ihh production and stimulate terminal chondrocyte differentiation, as shown by the 
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expression of osteopontin and other molecular markers (Kronenberg, 2003; Ornitz and 
Marie, 2002).  
1.3.2.3 CNP regulation of endochondral bone growth 
           The natriuretic peptide family consists of three structurally related peptides: atrial 
natriuretic peptide (ANP); brain natriuretic peptide (BNP); and c-type natriuretic peptide 
(CNP) (Pejchalova et al., 2007; Yasoda and Nakao, 2009). These molecules regulate a 
number of biological processes through intracellular cGMP pathways, by acting through 
two different membrane-bound receptors: GC-A (NPR-A) and GC-B (NPR-B) (Yasoda 
and Nakao, 2009). CNP acting through its receptor, NPR-B, plays an important role in 
endochondral ossification (Teixeira et al., 2008). A number of recent studies of genetic 
mouse models and organ cultures demonstrated its role in vivo and in vitro (Agoston et 
al., 2007; Chikuda et al., 2004; Chusho et al., 2001; Miyazawa et al., 2002; Pejchalova et 
al., 2007; Teixeira et al., 2008; Yasoda et al., 2004). CNP-deficient mice display 
dwarfism due to impaired endochondral bone formation (Chusho et al., 2001; Pejchalova 
et al., 2007). The deficient mice have a narrow growth plate with a significant reduction 
in the hypertrophic zone (Chusho et al., 2001; Miyazawa et al., 2002). Npr2 (NPR-B) KO 
mice have a similar bone phenotype as CNP KO mice (Bartels et al., 2004; Miyazawa et 
al., 2002). Metatarsals from fetal rats and tibia isolated from mouse embryos treated with 
CNP showed increased bone growth (Agoston et al., 2007; Mericq et al., 2000). 
Chondrocyte proliferation was modestly increased. The most significant characteristic of 
CNP treatment was increased hypertrophic zone length, due to both increase in size and 
number of hypertrophic chondrocytes (Agoston et al., 2007; Teixeira et al., 2008).  
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          However, while many extracellular regulators of cartilage development and 
transcription factors controlling growth plate function have been identified, much less is 
known about the intracellular signaling pathways. Over the years, nitric oxide (NO) has 
been identified not only in bone cell metabolism (van't Hof and Ralston, 2001) but also 
been shown to be involved in endochondral bone formation (Teixeira et al., 2005) and the 
communication between different cell types in bone (Ralston et al., 1995; van't Hof and 
Ralston, 1997). 
 
1.4 Nitric oxide and Bone 
1.4.1 The discovery of NO 
         Nitric oxide (NO) was first discovered as an endothelial-derived relaxation factor 
more than two decades ago (Furchgott, 1999; Ignarro, 1999).  NO physiology soon 
became one of the most rapidly growing research areas in biology. The importance of the 
pioneering work on this small molecule was recognized by the 1998 Nobel Prize in 
Physiology and Medicine to Drs. Robert F. Furchgott, Louis J. Ignarro, and Ferid Murad.   
1.4.2 The physiological functions of NO 
         NO can function as an intracellular messenger, an autacoid, a paracrine substance, a 
neurotransmitter, or as a hormone that can be carried to distant sites for the effects 
(Murad, 1999). The versatile functions of NO come from the chemical properties of the 
compound. NO is a gaseous uncharged free radical with an unshared electron that makes 
it easy to react with many molecules in order to regulate biological processes (Moncada 
et al., 1991).  Because it is uncharged, it can freely diffuse to the surrounding cells, 
making it ideal as a signaling molecule (Teixeira et al., 2008). In most processes, NO 
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activates soluble guanylyl cyclase (sGC) and causes increased levels of the intracellular 
secondary messenger cGMP (Moncada et al., 1991; Murad, 1999). However, the reactive 
properties of NO and the derivatives of NO were found to play important roles in its 
biological functions too (Lundberg et al., 2008; Marshall et al., 2004; Moncada et al., 
1991). For example, NO can interact with superoxide rapidly to form peroxynitrite, 
which is known to induce smooth muscle cell lipid peroxidation during inflammation 
(Lundberg et al., 2008).  The functions of NO cover almost every biological aspect, for 
example, in the cardiovascular system it causes vascular relaxation, prevents platelet 
aggregation, inhibits leukocyte adhesion and scavenges superoxide anions (Ignarro, 1999; 
Moncada and Higgs, 1993). It is also a neurotransmitter at synaptic endplates in the vagal 
system (Moncada and Higgs, 1993; Murad, 2006). The ultimate effects of NO are 
determined by its level, its origin, and by what else in the microenvironment it will react 
to (Moncada et al., 1991).  
1.4.3 NO synthesis and regulation 
         NO is generated through nitric oxide synthase (NOS) enzymes by oxidizing a 
guanidino nitrogen of L-arginine to NO and L-citrulline (Moncada and Higgs, 1993; 
Murad, 2006) (Fig. 1.4). NOS proteins use complex cosubstrates, including molecular 
oxygen, NADPH, FAD, FMN and heme iron groups, and require the cofactors 
calmodulin and BH4 to bind the enzyme as a homodimer (Murad, 2006). This reaction 
has to occur at adequate oxygen and cofactor levels (BH4, NADPH), or the uncoupling of 
the electron will form superoxide instead of NO (Moncada and Higgs, 1993; Murad, 
2006). The enzyme activity can be inhibited by substituted arginine analogues such as 
LNMMA and LNAME. NO can also be generated non-enzymatically from nitrite in the 
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Figure 1.4 Generation of NO from NOS.  
NO is formed by NOS enzymes through oxidizing a guanidino nitrogen of L-arginine to 
NO and L-citrulline. This reaction usually occurs at adequate oxygen and cofactor levels 
(BH4, NADPH). The enzyme activity can be inhibited by substituted arginine analogues 
such as L-NAME, and NO can also be generated pharmacologically by compounds in 
vitro such as organic nitrates, sodium nitroprusside or nitroglycerin. There are three NOS 
proteins, nNOS, iNOS and eNOS. nNOS and eNOS activities are regulated by 
intracellular calcium and calmodulin. Cytokines can induce iNOS to produce NO at a 
high level for a prolong time period.  
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acid environment of the stomach (van't Hof and Ralston, 2001) and pharmacologically by 
compounds such as organic nitrates, sodium nitroprusside or nitroglycerin, which have 
been used clinically for treatment of angina pectoris for over two centuries (Murad, 
1999). 
           Three different NOS proteins have been identified so far. The neuronal form of 
NOS (nNOS or NOS1) was first identified in brain (Moncada and Higgs, 1993), then 
found to be expressed in many cell types. The endothelial form of NOS (eNOS or NOS3) 
was first discovered in endothelial cells (Ignarro, 1999), but most cell types express 
eNOS. The inducible form of NOS (iNOS or NOS2) can be induced by LPS or many 
inflammatory cytokines in almost every cell type and plays an important role in 
inflammatory diseases (Furchgott, 1999) (Tab. 1.1). These proteins are encoded by three 
different genes on different chromosomes and have about 50-60% homology with each 
other and the cytochrome P450 enzymes (Murad, 2006).  
          Both eNOS and nNOS (collectively called cNOS) constitutively produce NO at 
low levels (picomolar range) in many cell types. Their activity is mainly regulated by 
changes in intracellular Ca2+ concentration and activities of calmodulin (Ignarro, 1999; 
Moncada et al., 1991; Scher et al., 2007). Expression of eNOS has been shown to be 
activated by phosphorylation at serine 1177 by many signaling pathways, such as heat-
shock protein (HSP90), Akt or acetylcholine (Ach) (Feelisch, 2008; Forstermann and 
Kleinert, 1995). Additionally, eNOS gene promoter activity is enhanced by shear stress 
and changes in estrogen levels (Armour et al., 2001a; Klein-Nulend et al., 1998; van't 
Hof and Ralston, 2001). Consistent with this, eNOS mRNA level has been found to be 
increased in endothelial cells after exposure to physiological concentration of estrogen 
25 
 
(Armour et al., 2001a) and in response to shear stress (Klein-Nulend et al., 1998). nNOS 
protein is found in the synaptic endplates, scarcoplasic reticulum, and mitochondria 
(Feelisch, 2008) and is upregulated upon activation of synaptic endplates in the central 
nervous system (Moncada et al., 1991). The regulation of nNOS expression seems to be 
very complex as reflected by at least eight different promoters transcribing eight different 
exon sequences in different cell types (Forstermann and Kleinert, 1995).  
              In contrast, iNOS is capable of generating large quantities of NO (nanomolar 
range) over a prolonged time period. However, because iNOS activity depends on 
transcription, response to external stimuli is not as rapid as that of cNOS. Properties of 
these three NOS are summarized in Table 1. (Tab. 1.1). Activation of the transcription 
factor NF-κB seems to be an essential step for iNOS induction in most cells (Feelisch, 
2008). iNOS can be activated by the endotoxin LPS and by pro-inflammatory cytokines, 
such as interleukin 1 (IL-1), tumor necrosis factor alpha (TNFα) and interferon γ (INFγ) 
through NF-κB pathways, whereas glucocorticoids and the anti-inflammatory cytokines 
IL-4, IL-10 and TGFβ are inhibitory (van't Hof and Ralston, 2001). It is now clear that 
the iNOS promoter is markedly upregulated by several cytokines and endotoxins 
(Forstermann and Kleinert, 1995). Interestingly, different combinations of cytokines 
differ in their abilities to produce NO in different cell types. For example, human 
chondrocytes can be induced by single cytokines such as IL-1β or TNFα to produce NO, 
whereas human primary osteoblasts require two or three cytokines for significant 
induction of NO production (Ralston, 1997). 
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Table 1.1 Sumary table of Nitric Oxide Synthases (NOS) 
 
Isoforms Examples of 
source
Calcium/
Calmodulin
Characters Examples of 
Function
Constitutive 
NOS
nNOS, NOS1 Brain Dependent Picomole NO 
fast release;
Short lasting;
Signaling 
molecule; 
Stimulated 
by Ach
Learning
eNOS, NOS3 Macrophage Dependent Vasodilation
Inducible
NOS 
iNOS, NOS2 Endothelium Independent Nanomole
NO slow 
release;
Long lasting;
Induced by 
cytokines 
Cytotoxicity
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         Additionally, high levels of NO produced by iNOS actually inhibit NF-κB activity 
itself, thus limiting iNOS and NO production in a negative feed-back loop (Moncada et 
al., 1991). Recently, cNOS were also found to be inducible by cytokines while iNOS was 
found constitutively expressed in many cell types (Feelisch, 2008) including 
chondrocytes (Rosa et al., 2008).  
 
1.4.4 Molecular pathways of NO action 
         NO is a gaseous uncharged free radical with an unshared electron, making it very 
reactive.  Because it is uncharged, it can freely diffuse to surrounding cells once it’s 
formed (Murad, 1999). In most processes, NO from cNOS serves as a messenger 
molecular and its physiological functions are mediated by its direct activation of the 
heme-containing moiety  of sGC in target cells (Collin-Osdoby et al., 1995). Activation 
of sGC causes an increase in the intracellular cGMP levels (Moncada and Higgs, 1993; 
Moncada et al., 1991). cGMP is a very important second messenger in many cell types 
and interacts with specific binding sites in target proteins, including cGMP-dependent 
protein kinases (PKG),  cGMP-binding proteins (e.g. phosphodiesterases, PDEs) and 
cGMP-dependent ion channels (e.g. ICH) (Feelisch, 2008; Murad, 2006) (Fig. 1.5). 
Activation of PKG triggers a cascade of phosphorylation events that culminate in the 
alteration of various cellular processes, e.g. cell proliferation, smooth muscle relaxation, 
cytotoxicity and neurotransmission (Collin-Osdoby et al., 1995). 
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Figure 1.5 Molecular pathways of NO in cartilage. 
Once NO is produced, it can freely diffuse to surrounding cells and activates sGC, which 
causes an increase in the intracellular secondary messenger cGMP levels. cGMP is a very 
important second messenger in many cell types and interacts with specific binding sites 
in target proteins, including cGMP-dependent protein kinases (PKG),  cGMP-binding 
proteins (e.g. phosphodiesterases, PDEs) and cGMP-dependent ion channels (e.g. ICH).  
An important role of cGMP-dependent protein kinase II (PKGII) in bone formation has 
been identified. Mice lacking PKGII or its upstream activator C-type natriuretic peptide 
(CNP) demonstrated severe skeletal phenotypes and dwarfism. Possible downstream 
pathways of cGKII include the inhibition of nuclear translocation of transcription factor 
SOX9, suppression of FGF signaling, and activation of MAPK (p38 and ERK).  (Adapted 
from Teixeira et al., 2008) 
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In contrast, high concentrations of NO, for example from iNOS, can bind to tyrosine or 
cysteine residues of many thiol containing proteins and lead to nitration and nitrosylation 
of the proteins (Lundberg et al., 2008; Marshall and Stamler, 2001; Stamler et al., 2001). 
For example, S-nitrosylation of glutathione, leads to inhibition of glutathione and other 
redox-signaling regulation pathways (Stamler et al., 2001).   
1.4.5 Mechanisms of nitrite, nitrate, peroxynitrite 
         The half life of NO is only a few seconds because it converts to nitrite and nitrate 
shortly after it is formed (Furchgott, 1999). These products have been used as markers of 
NO formation for a long time. It is clear now that these derivatives of nitrogen are 
responsible for many biological effects of NO. For example, nitrite has been shown to 
protect tissues against ischemia/reperfusion-related injuries in several organs (Feelisch, 
2008). This is particularly important for cartilage, because cartilage is an avascular tissue, 
and the oxygen level is only about 1-6% in deeper articular chondrocytes (Hirao et al., 
2006; Schipani et al., 2001). NO formation by NOS requires abundant oxygen levels, 
while nitrite formation is independent of oxygen. Therefore, when oxygen levels fall 
below a critical threshold, nitrite and nitrate react to mediate indirect effects of NO, and 
nitrite reduction to NO may serve to prevent a drop in NO concentration (Feelisch, 2008). 
         At the same time, NO can interact with superoxide to form the very reactive 
peroxynitrite and hydroxyl radicals that are responsible for tissue damage during 
inflammatory process by inducing lipid peroxidation (Feelisch, 2008).  Peroxynitrite 
becomes a marker for inflammation and formation of NO in many cell types (Stamler et 
al., 2001).   
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1.4.6 Expression of NOS proteins in cartilage  
         All three NOS proteins are expressed in chicken, and NO derivatives accumulate in 
the calcified region of the chicken cartilage (Teixeira et al., 2005), suggesting a role of 
NOS genes in cartilage development. iNOS was found spontaneously expressed in 
normal human articular cartilage, but at a higher level in chondrocytes from osteoarthritis 
(OA) (Rosa et al., 2008).  This implies an important role of iNOS in articular cartilage, 
and indeed iNOS is speculated to participate in almost every aspect of  OA 
pathophysiology (Abramson, 2008; Abramson et al., 2001; Amin and Abramson, 1998; 
Feelisch, 2008; van den Berg, 2001).   
          Over years NO has been known to regulate bone cell metabolism and bone 
remodeling (Abramson, 2008; Teixeira et al., 2008; van't Hof and Ralston, 2001). 
Recently, with the reported roles of cGKII and CNP as regulators of endochondral bone 
formation, the biological role of NO in bone formation has been investigated further. 
1.4.7 NO in cartilage development and endochondral bone formation  
         In vitro studies suggest that NO signaling is required for chondrocyte maturation 
(Teixeira et al., 2005).  In chicken cartilage, NO synthesis is required for development of 
the mature chondrocyte phenotype by upregulating alkaline phosphatase (ALP) and type 
X collagen expression (Teixeira et al., 2005). Inhibition of NOS, sGC, or cGK blocked 
retinoic-acid induced chondrocyte maturation in vitro (Kirimoto et al., 2005). High levels 
of NO, whether from nitric oxide donors or endogenously induced by cytokines, has been 
shown to induce chondrocyte apoptosis, and recently this apoptosis has been linked to 
generation of reactive oxygen species in chondrocyte (Lotz et al., 1999). Interestingly, a 
study showed that low levels of NO protect chondrocytes from cell death through 
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upregulation of heme oxygenase 1 (HO-1) and NF-κB, and concomitant downregulation 
of both extracellular signaling regulated protein kinases ERK 1/2 and p38 activation 
(Kim et al., 2005).  
            In recent years, a study of genetically altered mice discovered that eNOS gene 
knockout mice display reduced bone volume and bone formation at 6 weeks of age, but a 
normal bone phenotype was restored at 12-18 weeks (Aguirre et al., 2001). Another study 
showed that eNOS knockout mice present limb deficiencies with short digits, reduced 
weight and delayed growth (Hefler et al., 2001). It was proposed that these abnormities 
were caused by insufficient blood flow to the limbs and hemorrhage. However, the exact 
mechanism and role of eNOS in earlier stages of skeletal development is not well 
understood. Other groups demonstrated that nNOS knockout mice present higher bone 
mineral density in 10-week old female mice, particularly in trabecular bone (van't Hof et 
al., 2004). Moreover, administration of NOS inhibitors to drinking water of pregnant rats 
induced fetal growth retardation and hindlimb disruptions in pups (Diket et al., 1994). 
However, because of potential compensatory mechanism between the three NOS proteins 
and the possibility of non-specific actions of NOS inhibitors, the in vivo role of NO and 
NOS genes in endochondral ossification still waits to be elucidated.  
           Interestingly, double knockout mice for two NOS genes do not display significant 
growth defects  as  also shown for triply knockout mice of all three NOS genes (Sabanai 
et al., 2008; Teixeira et al., 2008). However, the double and triple knockout mice present 
high frequency of embryonic lethality and very low survival rates postnatally (15% in 
triple knockout mice) (Sabanai et al., 2008; Teixeira et al., 2008).  This suggests 
occurrence of major abnormalities during development in most embryos. Postnatal death 
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of triple knockout mice is mostly due to spontaneous myocardial infarction accompanied 
by severe coronary arteriosclerotic lesions (Nakata et al., 2008), but the surviving 
knockout mice surprisingly live a normal life. This suggests that other effects may 
compensate for loss of all three NOS genes. One study of triple knockout mice showed 
increased bone mineral density in 12-20 week-old mice, but these parameters were 
normal in younger (4 week-old) mice (Sabanai et al., 2008). This study also demonstrated 
increases in bone formation rate, mineral apposition rate, and serum alkaline phosphatase 
concentration in triple knockout mice (Sabanai et al., 2008). These results further confirm 
the role of NOS in bone homeostasis. More generally, analyses of mice with inactivation 
of two or all three NOS genes suggest that the phenotypes of these mice are variable, 
ranging from very mild phenotypes to lethality (Teixeira et al., 2008). More detailed 
studies on the knockout mice and other compensatory mechanisms need to be completed.  
1.4.8 Effects of NO on bone remodeling, osteoblasts and osteoclasts  
         NO appears to have biphasic effects on osteoblasts and osteoclasts. The constitutive 
production of NO at low concentrations promotes the proliferation and differentiation of 
osteoblasts and modulates osteoblast function. Some investigators have shown that slow 
release of NO donors stimulates osteoblast proliferation and differentiation in vitro, while 
NOS inhibitors had little effects on them (MacPherson et al., 1999). eNOS signaling was 
found to be important for the osteoblast lineage (Grassi et al., 2006). Several studies 
showed reduced bone formation in eNOS knockout mice accompanied by reduced 
osteoblast number and mineralization (alkaine phosphatase, ALP and mineral deposition) 
in vivo and in vitro (Aguirre et al., 2001). Additionally, eNOS signaling was shown to be 
essential for estrogen and mechanical loading induced bone formation (Armour et al., 
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2001a; Furchgott, 1999). Another study revealed that eNOS may act to mitigate an 
exaggerated state of estrogen-deficiency-induced bone remodeling (Aguirre et al., 2001). 
nNOS knockout mice present reduced bone remodeling with reduced remodeling surface 
and a reduction in osteoblast numbers in vivo (van't Hof et al., 2004). In contrast, high 
concentrations of NO are also inhibitory for the osteoblast lineage, and NO production 
induced by IL-1β, TNF-α, and IFN-γ appears to be partly responsible for the inhibitory 
effects on osteoblast proliferation (Evans and Ralston, 1996) and on the promotion of 
osteoblast differentiation and apoptosis (Lotz et al., 1999). As a result, high levels of NO 
and iNOS regulate osteoblast function and inhibit bone formation with important 
implications for the pathogenesis of inflammation-mediated osteoporosis (Armour et al., 
2001b).  
           These results also support the idea that moderate induction of NO potentiates bone 
resorption. NO therefore appears to be an important regulatory molecule for both 
osteoblast and osteoclast lineages and represents one of the molecules produced by 
osteoblasts which directly regulate osteoclastic activity (Evans and Ralston, 1996). 
          It is now well-established that a high concentration of NO is a potent inhibitor of 
osteoclast-mediated bone resorption. When combined with other cytokines, IFN-γ 
markedly induces NO production, which suppresses osteoclast formation and activity of 
mature osteoclasts (Brandi et al., 1995). This high concentration of NO is largely 
responsible for the selective inhibitory effect of IFN-γ on cytokine-induced bone 
resorption.   It is suggested that the inhibitory effects of NO on bone resorption are partly 
explained by induction of apoptosis in osteoclast progenitors rather than osteoclast 
formation (Ralston, 1997). Therefore, it is of interest to study the selectivity of NO-
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induced bone cell apoptosis and the communication between bone cells, and it is of 
clinical relevance that modulating NO concentrations may have therapeutical potential.  
           There is no evidence to support a role of eNOS for normal osteoclast formation 
and activity under physiological conditions in knockout mice (van't Hof and Ralston, 
2001). nNOS knockout mice present reduced bone remodeling and a reduction in 
osteoclast numbers in vivo, suggesting a role of nNOS in stimulation of bone turnover 
(van't Hof et al., 2004).  
1.4.9 Downstream targets of NO in bone 
         The cellular pathways downstream of NO in skeletal cells are complex and poorly 
understood. As discussed above, an important role of cGMP-dependent protein kinase II 
(PKGII) in bone formation has been identified (Chikuda et al., 2004; Pfeifer et al., 1996). 
Mice lacking PKGII or its upstream activator C-type natriuretic peptide (CNP) 
demonstrated severe skeletal phenotypes and dwarfism (Chusho et al., 2001; Miyazawa 
et al., 2002; Pejchalova et al., 2007; Pfeifer et al., 1996). Because both NO and CNP 
stimulate the production of cGMP via soluble or particulate guanylyl cyclases (GC) 
(Chusho et al., 2001), the cGMP/cGKII pathway would be a likely mediator of NO 
signaling in cartilage. Identification of the downstream targets of cGKII in bone 
formation is under investigation by several groups. Some studies of CNP signaling 
suggested that possible downstream pathways of cGKII include the inhibition of nuclear 
translocation of transcription factor SOX9 (Miyazawa et al., 2002), suppression of FGF 
signaling, and activation of MAPK (p38 and ERK) (Agoston et al., 2007; Teixeira et al., 
2008; Yasoda et al., 2004) (Fig. 1.5). In agreement with these models, IL-1 caused a 
release of FGF in rabbit articular chondrocyte and stimulated cell proliferation, which 
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was blocked by NOS inhibition (Jang and Murrell, 1998). However, cGKII is not the 
only downstream target of NO (Feelisch, 2008; Kim et al., 2005). The role of cGKI and 
the indirect effects of the NO derivatives nitrite, nitrate, and peroxynitrite in individual 
bone cells need to be studied further. 
 
1.5 Overall objectives and hypotheses 
1.5.1 Rational  
         Endochondral ossification is controlled by a process of chondrogenesis, 
chondrocyte proliferation, differentiation and eventually hypertrophy. During postnatal 
development, proliferation and hypertrophy occur in a controlled fashion in the cartilage 
growth plate, regulating the full length of adult bone. As we discussed above, NO 
promotes chondrocyte maturation and apoptosis in vitro, and NOS genes play an 
important role in bone formation and remodeling. However, little is known about the role 
of these genes in the cartilage growth plate and in early endochondral bone formation. 
The recent identification of CNP/cGMP/cGKII as important regulators of endochondral 
bone formation provides further motivation to study the role of NO/NOS in growth plate 
development and endochondral ossification. The overall objective of this study was to 
identify the effects of the NO/NOS pathways on specific events during the endochondral 
ossification process, in particular chondrocyte proliferation and hypertrophic 
differentiation.   
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1.5.2 Overall hypothesis  
         NOS/NO controls endochondral ossification by regulating chondrocyte 
proliferation and differentiation. 
 
1.5.3 Research plan and specific aims 
1.5.3.1 Aim 1: Analyze the roles of iNOS/NO in growth plate physiology and its 
interaction with the Rac1 gene in vivo 
Objective: We had shown recently that chondrocyte-specific deletion of the Rac1 gene in 
mice leads to severe dwarfism due to reduced chondrocyte proliferation, but the 
molecular pathways involved remained unclear. Our study examined the iNOS/NO 
pathway as a novel mediator of mitogenic Rac1 signaling and implicated it as a target for 
therapies for growth disorders.   
Hypothesis: iNOS/NO signaling mediates mitogenic signaling of Rac1 gene in cartilage 
Main findings:  
1. Rac1-deficient chondrocytes display severely reduced levels of iNOS protein and 
NO production. NO donors reversed the proliferative effects induced by Rac1 
deficiency, whereas inhibition of NO production mimicks the effects of Rac1 loss 
of function.   
2. Examination of the growth plate of iNOS-deficient mice revealed reduced 
chondrocyte proliferation and lower expression of cyclin D1, a key regulator of 
chondrocyte proliferation.  
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3. Rac1-NO signaling inhibits the expression of ATF3, a known suppressor of cyclin 
D1 expression in chondrocytes, identifying ATF3 as a link between Rac1/iNOS 
and the chondrocyte cell cycle.   
 
1.5.3.2 Aim 2: Characterize the roles of eNOS/NO pathway in growth plate 
physiology in vivo  
Objective: NO has been implicated both in the bone remodeling and pathogenesis of 
osteoarthritis, but the role of specific NOS enzymes in chondrocyte physiology is unclear. 
The objective of this study was to examine the effects of inactivation of eNOS on 
cartilage development using genetically modified mice.  
Hypothesis: eNOS/NO signaling promotes endochdondral bone growth through direct 
effects in growth plate chondrocytes. 
Main findings:  
1. eNOS-deficient mice show increased lethality and reduced bone growth, with 
hypocellular growth plates and a marked reduction in the number of proliferating 
chondrocytes.  
2. In vitro studies demonstrated lower chondrocyte numbers and reduced 
endochondral bone growth in mutants, suggesting that the role of eNOS signaling 
in chondrocyte proliferation is cell-autonomous.  
3. Reduced chondrocyte numbers appear to be caused by decreased cyclin D1 and 
increased p57 expression in mutants, resulting in slower cell cycle progression 
and earlier cell cycle exit.  
39 
 
4. The prehypertrophic markers P57, RORα and Hif-1α were expressed prematurely 
in mutant mice.  
 
1.5.3.3 Aim 3: Determine the roles of nNOS/NO pathway in cartilage growth plate in 
vivo 
Objective: We recently described the effects of eNOS deficiency on cartilage 
development. Interestingly we found an upregulation of nNOS transcription levels in 
eNOS-deficient cartilage. Therefore, now we extended these studies to mice deficient for 
nNOS. 
Hypothesis: nNOS/NO signaling promotes chondrocyte proliferation and inhibits 
differentiation in the cartilage growth plate in vivo. 
Main findings:  
1. nNOS-null mice show transient growth retardation and shorter long bones. nNOS-
deficient growth plates display a marked reduction in replicating proliferating 
chondrocytes.  
2. Histological sections also demonstrated thinner cortical bone and fewer trabeculae 
in mutant mice.  
3. Reduced chondrocyte numbers may in part be due to premature cell-cycle exit 
because of decreased cyclin D1 and increased p57 expression in mutants.  
4. Increased chondrocyte apoptosis was shown by increased cleaved-caspase 3 
staning in mutants. 
5. Expressions of prehypertrophic markers p57, RORα, and c-Fos were increased, 
while the expression of Hif1α was not changed in mutants.  
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2.1 Chapter summary 
       Coordinated proliferation and differentiation of growth plate chondrocytes controls 
endochondral bone growth and final height in humans, and disruption of this process 
results in diseases of the growing and adult skeleton such as chondrodysplasias or 
osteoarthritis. We had shown recently that chondrocyte-specific deletion of the Rac1 gene 
in mice leads to severe dwarfism due to reduced chondrocyte proliferation, but the 
molecular pathways involved remained unclear. Here, we demonstrate that Rac1-
deficient chondrocytes display severely reduced levels of iNOS protein and NO 
production. NO donors reversed the proliferative effects induced by Rac1 deficiency, 
whereas inhibition of NO production mimicks the effects of Rac1 loss of function.  
Examination of the growth plate of iNOS-deficient mice revealed reduced chondrocyte 
proliferation and expression of cyclin D1, a key regulator of chondrocyte proliferation. 
Finally, we demonstrate that Rac1-NO signaling inhibits the expression of ATF3, a 
known suppressor of cyclin D1 expression in chondrocytes, identifying ATF3 as a link 
between Rac1/iNOS and the chondrocyte cell cycle.  In conclusion, our studies identify 
the iNOS/NO pathway as a novel mediator of mitogenic Rac1 signaling and implicate it 
as a target for therapies for growth disorders.   
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2.2 Introduction 
         Growth of endochondral bones is regulated by the coordinated proliferation and 
differentiation of growth plate chondrocytes (Kronenberg, 2003; Olsen et al., 2000).  Cell 
volume increase during hypertrophy provides one driving force for bone growth, while 
ordered proliferation is required for generation of sufficient cell numbers for subsequent 
hypertrophy (Beier, 2005). Thus, inhibition of either proliferation or hypertrophy can 
both result in dwarfism. Numerous diseases are caused by disruption of these processes, 
for example by gene mutations, endocrine imbalances and mechanical or nutritional 
influences. Many growth factors and hormones have been shown to regulate chondrocyte 
proliferation, including fibroblast growth factors, parathyroid hormone-related peptide, 
and Indian hedgehog (Ballock, 2003; van der Eerden et al., 2003). However, the 
intracellular mechanisms controlling chondrocyte proliferation and hypertrophy are much 
less understood.  
          We have previously reported that chondrocyte-specific inactivation of the Rac1 
gene, encoding a Rho family GTPase with a central role in cellular signaling pathways, 
causes dwarfism and numerous skeletal abnormalities (Wang et al., 2007). A similar 
phenotype of reduced long bone growth was observed upon limb-specific inactivation of 
the Rac1 gene (Morita et al., 2007). Rho family GTPases act as molecular switches that 
become activated in response to specific extracellular stimuli through the activity of 
guanine nucleotide exchange factors (GEFs) that load GTP onto the GTPase (Heasman 
and Ridley, 2008; Vega and Ridley, 2007; Vega and Ridley, 2008). Activated Rho 
proteins then interact with a large variety of downstream effectors, including cytoskeletal 
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regulators and various kinases, to control a number of cellular events such as cell 
migration, cell cycle progression and gene expression.  
        The defects we observed in cartilage-specific Rac1 KO mice appear to be due, at 
least to a large part, to reduced chondrocyte proliferation (Wang et al., 2007), but the 
downstream mechanisms connecting Rac1 to chondrocyte proliferation are unknown. 
Rac1 has been shown to control many cellular processes, including actin dynamics, gene 
expression and generation of reactive oxygen species (ROS) (Bustelo et al., 2007; 
Hordijk, 2006). There are many interactions between ROS and NO (Thomas et al., 2008); 
however, NO or the enzymes involved in its synthesis have not been identified as major 
mediators of Rac1 signaling. Three different NOS have been identified, eNOS, iNOS and 
nNOS (endothelial, inducible and neuronal NOS, respectively) (Bryan et al., 2009). Here 
we identify iNOS as a novel target of Rac1 that mediates the mitogenic activities of this 
pathway during endochondral bone growth. 
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2.3 Materials and methods 
2.3.1 Animals and materials 
         Timed-pregnant CD1 mice were purchased from Charles River Laboratories at 
embryonic day 15.5 mice (E15.5). S-nitroso-N-acetylpenicillamine (SNAP), 2,2'-
(Hydroxynitrosohydrazino) bis-ethanamine (NOC-18), and the Rac1 inhibitor 
(NSC23766) were obtained from Calbiochem. N (G)-nitro-L-arginine methyl ester (L-
NAME), 3-morpholinosydnonimine (SIN-1) and sodium nitroprusside (SNP) were 
obtained from Sigma and reconstituted in Dimethyl sulfoxide (DMSO, vehicle) according 
to the manufacturer's instructions. Cell culture materials and general chemicals were 
obtained from Invitrogen, Sigma or VWR unless otherwise stated.  
         The following antibodies were employed in this study: iNOS #ab15323-500, and 
eNOS #ab3868-100 (abcam); Rac1 #sc-217, Nitrotyrosine #sc-32757, ATF3 #sc-188, 
Goat-anti-mouse #sc-2005, and Goat-anti-rabbit #sc-2004 (all from Santa Cruz 
Biotechnology); Cyclin D1 (SP4) #9104-S1 (NeoMarkers Inc.); BrdU #03-3900 (Zymed 
Laboratories). 
2.3.2 Mouse breeding and genotyping 
         Mice with a deletion of the iNOS gene (NOS2tm1Lau, stock# 002609) (Laubach et al., 
1995) and control mice with C57/BL6 background were obtained from Jackson 
Laboratory (Bar Harbor, ME), and exposed to a 12-h light–dark cycle and fed tap water 
and regular chow at libitum. All procedures involving animals were approved by the 
University of Western Ontario Animal Care and Use Committee. For PCR genotyping, 
tail snips were used to prepare DNA for PCR analysis. PCR genotyping was performed 
by simultaneous amplification of the wild-type and null iNOS alleles as described 
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(Tranguch and Huet-Hudson, 2003). PCR fragments were analyzed by agarose gel 
electrophoresis.  
2.3.3 Primary cell culture and treatments 
         Primary chondrocytes were isolated essentially as described (James et al., 2006; 
Woods et al., 2009c). Long bones from limbs were isolated from E15.5 mouse embryos 
and placed in α-MEM media (Invitrogen) containing 0.2% Bovine Serum Albumin 
(BSA), 1 mM β-glycerophosphate, 0.05 mg/ml ascorbic acid and penicillin/streptomycin. 
Then the medium was removed and the bones placed in 4 ml of 0.25% trypsin-EDTA 
(Invitrogen) for 15 min at 37°C. Trypsin was subsequently replaced with 1 mg/ml 
collagenase P (Roche) in DMEM/10% fetal bovine serum (Invitrogen), and cells were 
incubated at 37°C with rotation at 100 rpm for 90 min. Following digestion, the cell 
suspension was centrifuged for 5 min at 1000 rpm, and the collagenase containing 
supernatant was decanted. Chondrocytes were resuspended in medium containing 2:3 
DMEM:F12, 10% fetal bovine serum, 0.5 mM L-glutamine, and penicillin/streptomycin 
(25 units/ml). Cells were seeded in 6-well NUNC plates at a density of 5 × 104 cells per 
ml and incubated overnight. Primary monolayer chondrocytes were treated with 10-3 M 
L-NAME, 10-5 M SNAP or NOC-18 or the DMSO control (vehicle) diluted in fresh 
media supplemented with 0.25 mM ascorbic acid (Sigma) and 1 mM β-glycerophosphate 
(Sigma) and incubated for up to 5 days with replacement of the medium and treatments 
every other day.  
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2.3.4 Adenoviral infections 
         Adenovirus expressing Cre Recombinase or GFP (control) was purified using the 
Adeno-XTM virus mini-purification kit (Clontech) and incubated with primary 
chondrocytes from Rac1fl/fl mice at a multiplicity of infection (MOI) of 50. Four hours 
after culturing, medium was changed and cells were cultured as described above. 
2.3.5 ROS and NO measurements 
         Intracellular ROS and NO were measured fluorometrically. The nonfluorescent dye 
2′,7′-dichlorofluorescein diacetate (DCF-DA) permeated cells easily and hydrolyzed to 
fluorescent 2′,7′-dichlorofluorescein (DCF) upon interaction with intracellular ROS. 
Cultured cells were washed twice with PBS. Cells were then incubated with 20 μM of 
DCF-DA for 30 min and washed with PBS. The DCF fluorescence was analyzed using a 
fluorometer (SAFIRE microplate reader, TECAN, Australia) at an excitation of 485 nm 
and an emission of 530 nm. Nitric oxide production in chondrocytes was analyzed using 
DAF-FM DA (4-amino-5-methylamino-2',7'-difluorofluorescein diacetate), a 
fluorescence probe specific for NO, that was added (10 μM) to cells. The probe was 
diluted in culture medium. Cells were incubated with DAF-FM for 30 min at 37°C and 
and then washed with PBS. Measurements were made using the SAFIRE microplate 
reader (TECAN, Australia; excitation, 495 nm; emission, 515 nm). 
2.3.6 Cell proliferation assay  
         Cell proliferation assays were performed using CyQUANT NF Cell Proliferation 
Assay Kit (Invitrogen) according to manufacturer’s protocol, as described (Yan et al., 
2010). Chondrocytes were isolated as described above and seeded in 96-well NUNC 
plates at a density of 1000 cells/100µl/well. After treatment, the medium was discarded 
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and replaced with CyQUANT NF dye reagent diluted in HBSS buffer and incubated for 
30 min in 37oC incubator. Measurement of the fluorescence intensity of each sample was 
done using SAFIRE microplate reader (TECAN, Australia) with excitation at 480 nm and 
emission detection at 520 nm with a minimum of 6 individual wells per treatment in 
duplicate and three independent cell isolations. Images of primary chondrocyte were 
taken after treatments of 1 day in culture using a Nikon SMZ1500 microscope with 
Photometric CoolSNAP colour digital camera (Nikon Canada) and PTI Image Master 5 
program. 
2.3.7 Tibia organ culture 
         Tibiae were isolated from E15.5 embryos from CD1 timed-pregnant mice (Charles 
River Canada) using the Stemi DV4 Stereomicroscope (Zeiss) as described (Agoston et 
al., 2007; Wang et al., 2007). Dissection day was considered to be day 0 and tibiae were 
allowed to recover from dissection overnight in serum-free α-MEM media containing 
0.2% BSA, 0.5 mM L-glutamine, 40 units penicillin/mL and 40 μg streptomycin/mL as 
described (Agoston et al., 2007). The following morning, bones in 24-well Falcon plates 
were measured using an eyepiece in the Stemi DV4 Stereomicroscope and treated with 
10-3 M L-NAME, 10-5 M SNAP or NOC-18 or 5 X 10-5 M Rac1 inhibitor (NSC23766) 
with or without 10-5 M SNP, and DMSO as the vehicle. Medium was changed every 48 
hrs beginning on day 1, and bones measured on days 1, 3 and 6. Results are expressed as 
change in length relative to day 1. Experiments were repeated at least three times, with 4–
6 bones per treatment for each trial. 
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2.3.8 Histology, immunohistochemistry and BrdU labeling 
         Tibia samples from organ cultures or newborn mice were rinsed with PBS and fixed 
in 4% paraformaldehyde overnight. Bones were then placed in 10% formalin solution, 
and sent for embedding and sectioning in the Pathology lab at the Molecular Pathology 
Core Facility at the Robarts Research Institute (London, Ontario, Canada). Following 
sectioning, bones were stained with hematoxylin and eosin or safranin O/fast green using 
standard protocols (Solomon et al., 2009; Wang et al., 2007; Yan et al., 2010). For 
immunohistochemistry, sections were incubated with primary anti-Cyclin D1 antibody 
(1:50 dilution, NeoMarkers), anti-ATF3 antibody (1:200 dilution, Santa Cruz), anti-
nitrotyrosine antibody (1:200 dilution, Santa Cruz) or anti-iNOS antibody (1:1000 
dilution, abcam) overnight at 4°C. For BrdU labeling, newborn mice were injected 1h 
before sacrifice intraperiteally with BrdU (Roche) at a dose of 0.01 ml/g body weight. 
BrdU was detected in paraffin sections using anti-BrdU antibody (1:100 dilution, Zymed 
Laboratories). Bound antibody was visualized using the UltraVision LPValue detection 
system (Lab Vision) with AEC chromogen substrate (Lab Vision). 
2.3.9 RNA isolation, and real-time RT-PCR  
         Total RNA was isolated from epiphyseal cartilage of long bone from newborn mice 
or primary cells using TRIzol (Invitrogen), according to the manufacturer's 
recommendations. Taqman real-time PCR was performed as described (James et al., 
2006; Woods et al., 2005) with primers and probe sets from Applied Biosystems (ATF3 
Mm00476032_m1; Gapdh Mm99999915_g1).  Data were normalized to Gapdh mRNA 
levels and represent averages and SEM from direct comparison of mutant and control 
littermates from three different crosses.  
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2.3.10 Statistical analysis 
           Statistical significance was determined by Student’s T-Test or by one-way 
ANOVA with Bonferroni post test using GraphPad Prism version 4.00 for Windows, 
GraphPad Software, San Diego California USA, www.graphpad.com. In figures where 
values are shown as percentages, data were first log-transformed before applying 
ANOVA. 
 
2.4 Results 
2.4.1 Rac1 deficiency results in reduced iNOS expression and NO production  
         We have previously shown hypocellularity and reduced proliferation in Rac1-
deficient growth plates (Wang et al., 2007). We first examined whether we could 
recapitulate this phenotype in vitro to facilitate biochemical studies on the underlying 
mechanisms. Primary chondrocytes were isolated from Rac1fl/fl mice, carrying two alleles 
of a conditional (floxed) Rac1 allele. Cells in monolayer culture were infected with 
adenoviruses expressing green fluorescent protein (GFP, control) or Cre recombinase. 
Infection with Ad-Cre resulted in a marked reduction of Rac1 protein (Fig. 2.1A); 
densitometry determined that Rac1 proteins levels were reduced by 70 % in Ad-Cre-
infected cultures (data not shown). Control cells increased their numbers steadily over the 
three-day time course of the experiment, whereas cells infected with Ad-Cre multiplied at 
a much slower rate (Fig. 2.1B). This was accompanied by reduced expression of cyclin 
D1 (Fig. 2.1C), as we had observed in vivo.  These data documented that our in vitro 
culture  
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Figure 2.1 iNOS expression and NO generation are reduced in Rac1-deficient 
chondrocytes.  
Primary chondrocytes were isolated from Rac1fl/fl mice and infected with adenovirus 
expressing green fluorescent protein (GFP, control) or Cre recombinase. Infection with 
Ad-Cre resulted in approximately 70 % reduction of Rac1 protein (A). Cell counts 
demonstrated that control cells increased their numbers steadily over the three-day time 
course of the experiment, whereas cells infected with Ad-Cre multiplied at a much slower 
rate (B). This was accompanied by reduced expression of cyclin D1 in mutant cells, 
compared to control (C). Rac1 deletion reduced ROS levels, but caused a more 
pronounced reduction in NO production (D) in Cre recombinase-infected cells. Western 
blotting demonstrated markedly reduced expression of iNOS protein in Cre-expressing 
chondrocytes, whereas eNOS expression was similar to control cells (E). By 
immunohistochemistry, iNOS staining was notably reduced in growth plates from 
cartilage-specific Rac1 KO mice compared to control mice (F). Scalebar: 50µm. A 
similar decrease in staining in mutant mice was observed for nitrotyrosine, an indicator of 
cellular NO levels (G). Scalebar: 100µm. Figures are representative of 3 independent 
trials. 
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system provides a good model to study the effects of Rac1 deletion on chondrocyte 
proliferation.  
Since Rac1 is able to stimulate ROS generation, we measured levels of ROS and 
NO. Rac1 deletion caused an approximately 50 % reduction in ROS levels, but NO 
production was inhibited to a much larger degree (Fig. 2.1D). We therefore examined the 
molecular cause of reduced NO production and showed that expression of iNOS protein 
was markedly reduced in Rac1-deficient chondrocytes, whereas eNOS expression was 
similar to control cells (Fig. 2.1E). To analyze effects of Rac1 deficiency on iNOS 
expression in vivo, we performed immunohistochemistry of paraffin sections from 
control and cartilage-specific Rac1 KO mice. In control mice, iNOS protein was found 
mostly in late proliferating and prehypertrophic chondrocytes (Fig. 2.1F). iNOS staining 
was notably reduced in growth plates from mutant mice that also showed disorganization 
of the proliferative zone, as we described earlier (Wang et al., 2007). A similar decrease 
in staining in mutant mice was observed using an antibody for nitrotyrosine, an indicator 
of cellular NO levels (Fig. 2.1G). Collectively, these data suggest that iNOS expression 
and NO generation are severely reduced in Rac1-deficient chondrocytes.  
 
2.4.2 NO promotes chondrocyte proliferation in cell and organ culture 
         We next examined whether addition of exogenous NO could overcome the effects 
of Rac1 deficiency. Addition of SIN-1, which induces both ROS and NO generation, 
rescued the numbers of Rac1-deficient chondrocytes in monolayer culture (Fig. 2.2A). In 
parallel, we treated cells with the phorbol ester PMA (an inducer of ROS only that did 
not change NO levels; data not shown) and observed no effects on chondrocyte numbers,  
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Figure 2.2 NO can rescue the effects of Rac1 deficiency. 
Primary chondrocytes were isolated from Rac1fl/fl mice and infected with adenoviruses 
expressing green fluorescent protein (GFP, control) or Cre recombinase. Addition of 
SIN-1, but not PMA, in this culture system increased numbers of Rac1-deficient 
chondrocytes (A). Western blotting showed that cyclin D1 expression in primary 
chondrocytes was restored by SIN-1, but not PMA (B). Incubation of chondrocytes with 
the NOS inhibitor L-NAME reduced chondrocyte cell numbers, while the NO donors 
SNAP and NOC18 caused an increase in chondrocyte cell numbers (C and D). Scale bar 
for C: 50µm. Figures are representative of 3 independent trials. 
 
 
 
 
 
 
 
 
 
60 
 
 
 
 
 
D
CA
B
CD1
β-actin  
Con    KO        Con   KO         Con    KO
DMSO         PMA            SIN-1 
DMSO LNAME NOC18 SNAP
0
15
30
45
*
*
R
el
at
iv
e 
flu
re
nc
en
ce
 d
en
si
ty
(C
yQ
U
A
N
T)
0
5
10
15
20
25
ce
ll 
nu
m
be
rs
(x
10
5 /m
l)
Ad-GFP Ad-Cre
DMSO           PMA              SIN-1
C
el
l n
um
be
rs
(x
10
5 /m
l)
* *
DMSO                         LNAME
NOC18                      SNAP
 
 
 
 
 
 
 
 
61 
 
suggesting that the mitogenic defects in Rac1-deficient chondrocytes are not due to lower 
ROS production. Similarly, Western blotting demonstrated that cyclin D1 expression in 
Rac1-deficient chondrocytes is restored by SIN-1, but not PMA (Fig. 2.2B). These data 
suggested that NO production is required for Rac1-induced chondrocyte proliferation and 
that inhibition of NO synthesis by other means would result in similar phenotypes as 
deletion of Rac1, while NO donors should increase chondrocyte proliferation. To test this 
prediction, we incubated chondrocytes with the NOS inhibitor L-NAME and the NO 
donors SNAP and NOC18. L-NAME reduced chondrocyte cell numbers, while both 
donors increased cell numbers (although only SNAP reached statistical significance; Fig. 
2.2C and D). Collectively, these data suggest a model where Rac1 promotes chondrocyte 
proliferation through iNOS/NO-mediated induction of cyclin D1 expression. 
We next examined how NO regulates chondrocyte proliferation and tissue 
architecture in intact growth plates using an organ culture system of embryonic mouse 
tibiae (Agoston et al., 2007). Tibiae were grown with DMSO (control) and L-NAME for 
six days. Measurement of growth plate zones in H&E-stained tissue sections 
demonstrated that L-NAME treatment resulted in a shortened proliferative zone, while 
the resting and hypertrophic zones of the growth plate were not affected (Fig. 2.3A and 
B). This was accompanied by reduced numbers of BrdU-incorporating cells (Fig. 2.3C 
and D).  
2.4.3 NO donors rescue the effects of Rac1 inhibition on bone growth 
         To investigate whether NO donors can rescue effects of Rac1 inhibition in intact 
growth plates, tibiae were incubated with the pharmacological Rac1 inhibitor NSC23766 
(Gao et al., 2004). Our earlier studies had demonstrated that this compound has similar  
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Figure 2.3 Inhibition of NO production results in reduced proliferation in tibia 
organ cultures.  
Tibiae isolated from E15.5 mice were incubated in organ culture with DMSO or the NOS 
inhibitor L-NAME (1mM). After six days, tibiae were fixed, embedded and sectioned, 
and sections were stained with hematoxylin and eosin (H&E). Staining and measurement 
of zone length demonstrated a shorter proliferative zone in L-NAME treated tibiae (A; 
red arrow: proliferating cell zone; blue arrow: hypertrophic cell zone A, B; RZ; resting 
zone, PZ: proliferative zone, HZ; hypertrophic zone. Scale bar 250 µm). This was 
accompanied by reduced numbers of BrdU-incorporating (C and D; dark brown nuclei; 
Scale bar 100 µm). Immunohistochemistry figures are representative of 3 independent 
trials.  
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effects on early chondrogenesis as genetic inactivation of Rac1, providing evidence for 
the specificity of the inhibitor (Woods et al., 2007a). NSC23766 treatment for six days 
resulted in drastic reduction of bone growth in our organ culture system (Fig. 2.4A and 
B), accompanied by shortening of the proliferative zone (Fig. 2.4C). The NO donor SNP 
did not affect bone growth on its own, but completely rescued the effects of Rac 
inhibition on overall tibia growth and the length of the proliferative zone (Fig. 2.4A-C). 
These data demonstrate that restoration of NO signaling overcomes the effects of Rac1 
deficiency in the authentic three-dimensional context of the growth plate.  
 
2.4.4 Reduced chondrocyte proliferation in iNOS-deficient mice 
         Since our data suggested a role for endogenous Rac1-iNOS signaling in growth 
plate chondrocyte proliferation, we next analyzed the cartilage phenotype of iNOS-
deficient mice (Laubach et al., 1995). Growth plates from these mice showed normal 
zonal and columnar architecture, but appeared slightly hypocellular in their centers (Fig. 
2.5A), similar to but more subtle than those of mice with cartilage-specific deletion of the 
Rac1 gene (Wang et al., 2007). Cell counts confirmed hypocellularity in the proliferative 
zone of mutant mice (Fig. 2.5B). Immunohistochemistry and counts of positive cells 
demonstrated lower numbers of chondrocytes incorporating BrdU (Fig. 2.5C and D) and 
expressing cyclin D1 (Fig. 2.5E and F) in iNOS-deficient growth plates. Both of these 
features had also been observed in cartilage-specific Rac1 KO mice (Wang et al., 2007).  
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Figure 2.4 The NO donor SNP rescues the effects of Rac inhibition in organ culture.             
E15.5 tibiae were incubated with control medium, the Rac inhibitor NSC23766 (50 µM), 
the NO donor SNP (10 µM) or both for six days. Rac inhibition resulted in drastic 
reduction of bone growth in our tibia organ culture system (A and B), accompanied by 
shortening of the proliferative zone (C). The NO donor SNP (10 µM) did not affect bone 
growth on its own, but completely rescued the effects of Rac inhibition on growth and the 
length of the proliferative zone (A-C).  Scale bar 100 µm. Images are representative of 3 
independent trials. 
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Figure 2.5 Reduced chondrocyte proliferation in iNOS KO mice.  
Growth plates from iNOS mutant mice were hypocellular (A), as shown by Safranine 
O/Fast Green staining. Cell counts confirmed hypocellularity in the proliferative zone of 
mutant mice (B). Immunohistochemistry and counts of positive cells demonstrated lower 
numbers of chondrocytes incorporating BrdU (C and D) and expressing cyclin D1 (E and 
F) in iNOS-deficient growth plates. Scalebar for A 250 µm, C and E 100 µm. Images are 
representative of 3 independent trials. 
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2.4.5 The transcriptional repressor ATF3 is upregulated upon loss of Rac1 or iNOS 
         We had shown earlier that cyclin D1 expression in chondrocytes is positively 
regulated by the transcription factors ATF-2 and CREB and repressed by ATF3 (Beier et 
al., 2001; Beier et al., 1999a; James et al., 2006). Immunohistochemistry demonstrated 
limited expression of ATF3 protein in chondrocytes of control mice, but markedly 
increased numbers of stained cells upon loss of Rac1 (Fig. 2.6A). In agreement with these 
data, ATF3 mRNA levels were increased in Rac1-deficient cartilage in vivo (Fig. 2.6B) 
and in primary Rac1fl/fl chondrocytes infected with Ad-Cre (Fig. 2.6C). This suggests 
premature induction of ATF3 which in turn can repress cyclin D1 transcription and result 
in earlier cell cycle withdrawal. SIN-1 treatment reduced ATF3 protein levels both in 
control chondrocytes and in Rac1-depleted chondrocytes in cell culture (Fig. 2.6D), 
suggesting that NO represses ATF3 expression. Finally, the number of ATF3-expressing 
chondrocytes is increased and its expression domain is expanded in iNOS KO growth 
plates, similar to Rac1 mutants (Fig. 2.6E). These data suggest that the Rac1-iNOS-NO 
pathway acts to suppress ATF3 expression in order to maintain cyclin D1 transcription 
and chondrocyte proliferation. 
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Figure 2.6 ATF3 suppresses cyclin D1 expression and inhibit chondrocyte 
proliferation. 
 Immunohistochemistry demonstrated relatively little expression of ATF3 protein in 
control mice (see also in magnification in right panel), with markedly increased 
expression upon loss of Rac1 (A). Scale bar 50 µm. Real-time RT-PCR demonstrated that 
ATF3 mRNA levels are increased in Rac1-deficient cartilage in vivo (B) and in primary 
Rac1fl/fl chondrocytes infected with Ad-Cre (C). SIN-1 treatment reduced expression of 
ATF3 protein in primary wild type and Rac1-deficient chondrocytes, while PMA did not 
affect either (D). The number of ATF3-expressing chondrocytes was increased in iNOS 
KO growth plates, similar to Rac1 mutants (E). Scale bar 100 µm. Figures are 
representative of 3 independent trials. 
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2.5 Discussion 
       Chondrocyte proliferation is one of the main determinants of endochondral bone 
growth and thus final height. While many extracellular signals that control these 
processes are known, the intracellular signaling pathways connecting cell surface 
receptors to specific cell cycle genes are less well understood. We had shown that the 
small GTPase Rac1 is essential for normal chondrocyte proliferation and cyclin D1 
expression, but the molecular mechanisms involved were not known. Here we 
demonstrate that Rac1 controls chondrocyte proliferation by stimulation of iNOS 
expression and NO production, which in turn suppresses ATF3 expression and thus 
allows increased transcription of the cyclin D1 gene (Fig. 2.7).  
        While the regulation of ROS generation by Rac1 is well established, there has been 
much less attention on interactions between Rac proteins and NO signaling. The 
requirement for Rac1 for normal iNOS expression in our study is consistent with an 
earlier report showing reduced iNOS mRNA levels upon adenoviral delivery of 
dominant-negative Rac to rat livers (Harada et al., 2003). However, Rac1 activation or 
inhibition did not alter iNOS induction by interleukin 1β in smooth muscle cells (Finder 
et al., 2001), suggesting that the connections between both pathways are stimulus- and/or 
cell type-specific. Interestingly, Rac1 deficiency in endothelial cells leads to reduced 
expression and activity of eNOS (Sawada et al., 2008), while eNOS protein levels were 
not altered in our system. These data suggest that the connections between Rac1 (and 
possibly other Rho GTPases) and components of the NO signaling pathway are 
connected in a cell type-specific manner. In addition, it appears likely that   
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Figure 2.7 Model of Rac1 –iNOS/NO – ATF3 – cyclin D1 signaling in chondrocytes. 
Our data show that Rac1 is required for normal levels of iNOS expression and NO 
production in chondrocytes. NO suppresses expression of ATF3, which acts as 
transcriptional repressor of cyclin D1. In Rac1- or iNOS-deficient chondrocytes, ATF3 
levels are increased, resulting in reduced activity of the cyclin D1 promoter which in turn 
slows chondrocyte proliferation and induces premature cell cycle exit. 
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the Rac1-iNOS interaction demonstrated by us is not exclusive; for example, Rac1 
probably acts through additional effectors including ROS and the actin cytoskeleton, and 
iNOS activity and expression in chondrocytes is likely controlled by additional upstream 
regulators. 
          NO and NOS genes have been studied extensively in the context of bone 
remodeling and arthritis (Scher et al., 2007; van't Hof and Ralston, 2001), but much less 
is known about the roles of this pathway in endochondral bone development (Teixeira et 
al., 2008). Teixeira and colleagues had shown that excess NO promotes hypertrophic 
differentiation and apoptosis of chondrocytes in chicken (Teixeira et al., 2005; Teixeira et 
al., 2001), while our data suggest that basal levels of NO are required for chondrocyte 
proliferation. Studies from other tissues suggest that the role of iNOS in cellular 
proliferation is cell-type and/or context-specific; for example, iNOS is required for 
hepatocyte proliferation during liver regeneration (Yasoda et al., 2009) but suppresses 
proliferation of smooth muscle cells (Kibbe et al., 2000). However, to our knowledge 
neither ATF3 nor cyclin D1 have been implicated in the mitogenic or anti-mitogenic 
effects of iNOS. It should be noted that since in vitro data from our and other laboratories 
suggest Rac1 functions during chondrocyte hypertrophy (Kerr et al., 2008; Wang and 
Beier, 2005), it is quite possible that iNOS or other NOS enzymes also contribute to this 
role of Rac1. 
           Interestingly, we recently demonstrated a similar phenotype as described here (e.g. 
reduced proliferation and cyclin D1 expression, increased levels of ATF3 and premature 
cell cycle exit) in mice deficient for the eNOS gene (Yan et al., 2010). Together, these 
studies suggest a dose-dependent effect of nitric oxide in the growth plate where low 
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levels are required for proliferation, but high levels promote terminal differentiation and 
ultimately apoptosis. This model is in agreement with suggested dose-dependent effects 
of NO (Thomas et al., 2008). The overlap in phenotypes in this and our earlier study (Yan 
et al., 2010) also imply partial overlap of iNOS and eNOS function in chondrocytes. NO 
generated from either source inhibits the onset of ATF3 expression, allowing continued 
expression of cyclin D1 and thus delaying cell cycle exit. However, eNOS expression 
was not affected by loss of Rac1, suggesting that the two genes are regulated by different 
upstream pathways and mediate mitogenic responses to different external stimuli.  
          In conclusion, this study identified the iNOS/NO pathway as a central mediator of 
the mitogenic activity of Rac1 in growing endochondral bones. Further research into this 
will provide us with novel approaches towards the treatment of various skeletal diseases 
such as chondrodysplasias.  
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3.1 Chapter summary 
         Nitric oxide (NO) and aberrant chondrocyte differentiation have both been 
implicated in the pathogenesis of osteoarthritis, but whether these processes are 
connected is unknown, and the role of specific nitric oxide synthase (NOS) enzymes in 
chondrocyte physiology is unclear. The objective of this study was to examine the effects 
of inactivation of endothelial nitric oxide synthase (eNOS) on cartilage development in 
mice. Skeletal growth and development of mice carrying a null mutation in the eNOS 
gene was studied in comparison to control littermates. In situ analyses were 
complemented by experiments with primary chondrocytes and tibial explants from these 
mice. eNOS-deficient mice show increased lethality and reduced bone growth, with 
hypocellular growth plates and a marked reduction in the number of proliferating 
chondrocytes. In vitro studies demonstrated lower chondrocyte numbers and reduced 
endochondral bone growth in mutants, suggesting that the role of eNOS signaling in 
chondrocyte proliferation is cell-autonomous. Reduced chondrocyte numbers appear to 
be caused by decreased cyclin D1 and increased p57 expressions in mutants, resulting in 
slower cell cycle progression and earlier cell cycle exit. In addition, expression of early 
chondrocyte markers such as Sox9 was reduced and prehypertrophic markers were 
expressed prematurely in mutant mice. Our data identify a novel and important role of 
eNOS in chondrocyte proliferation and endochondral bone growth and demonstrate that 
loss of eNOS results in premature cell-cycle exit and prehypertrophic chondrocyte 
differentiation during cartilage development.  
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3.2 Introduction 
Nitric Oxide  (NO) plays an important role in the progression of osteoarthritis 
(OA), in part by influencing the physiology of chondrocytes (Abramson, 2008). NO is 
synthesized through L-arginine by nitric oxid synthases (NOS) in many cell types. Three 
different types of NOS have been identified. The neuronal (nNOS or NOS1) and 
endothelial (eNOS or NOS3) forms are constitutively expressed, and their activity is 
regulated by intracellular signaling and the calcium binding protein calmodulin (van't Hof 
and Ralston, 2001). The inducible form (iNOS or NOS2) is stimulated at the level of 
expression by factors including lipopolysaccharide and cytokines, such as IL-1, TNFα 
and IFNα, and leads to a sustained and high levels of NO, mainly in inflammatory disease 
(Abramson, 2008; Mungrue et al., 2003). 
Changes in the articular chondrocyte phenotype, such as initiation of hypertrophic 
differentiation, are thought to play an important role in the pathogenesis of OA (Appleton 
et al., 2007; Drissi et al., 2005; Gauci et al., 2008). Physiologically, chondrocyte 
hypertrophy occurs in the process of endochondral ossification that gives rise to most 
bones in the vertebrate skeleton, such as the long bones of the limbs (Karsenty and 
Wagner, 2002; Zelzer and Olsen, 2003). Endochondral ossification involves the 
formation of a highly controlled and precisely shaped cartilage template that is 
subsequently replaced by bone tissue and bone marrow (Wagner and Karsenty, 2001). 
Once mesenchymal cells commit to the chondrogenic lineage, the subsequent events of 
endochondral bone formation occur through the epiphyseal growth plate (Olsen, 1999), 
which consists of zones of resting, proliferating, and hypertrophic  chondrocytes 
organized in distinguishable columnar arrays (Wagner and Karsenty, 2001). Within the 
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growth plate, proliferation of chondrocytes occurs in a unidirectional manner, resulting in 
longitudinal bone growth (Goldring et al., 2006; Kronenberg, 2003). After exiting the cell 
cycle, chondrocytes start to differentiate into prehypertrophic and eventually hypertrophic 
chondrocytes (Hoffmann and Gross, 2001; Mackie et al., 2008; Stanton et al., 2003). 
Hypertrophic chondrocytes direct mineralization of the surrounding extracellular matrix, 
attract blood vessel invasion, and ultimately undergo apoptosis while being replaced by 
bone and bone marrow (Kronenberg, 2003; Olsen et al., 2000). Proliferation and 
hypertrophy of growth plate chondrocytes and extracellular matrix production drive the 
longitudinal growth of endochondral bones and eventually determine body length in 
mammals (Kronenberg, 2003; Okazaki and Iwamoto, 2006).  
Since both NO signaling and altered chondrocyte differentiation contribute to OA, 
it is important to examine whether both processes are connected. Studies in the chicken 
suggest that NO signaling promotes chondrocyte hypertrophy (Teixeira et al., 2008; 
Teixeira et al., 2005), but the roles of NO and in particular the individual NOS genes in 
mammalian cartilage development are not well understood. In this study, we used a 
genetic approach to address the role of eNOS in chondrocyte differentiation and 
endochondral ossification in vivo. Inactivation of the eNOS gene resulted in a number of 
phenotypes, including reduced proliferation and earlier cell cycle exit of chondrocytes. 
Overall, these data provide novel information regarding the importance of eNOS/NO 
signalling in chondrocyte development and identify downstream regulators of 
endochondral ossification. 
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3.3 Materials and methods 
3.3.1 Animals and materials 
Timed-pregnant CD1 mice were purchased from Charles River Laboratories. Cell 
culture materials and general chemicals were obtained from Invitrogen, Sigma or VWR 
unless otherwise stated. The following antibodies were employed in this study: Kip2/p57 
#sc8298 (rabbit antibody against human protein), RORα #sc28612 (rabbit antibody 
against human protein), ATF3 #sc188 (rabbit antibody against human protein), Goat-anti-
mouse #sc2005, Goat-anti-rabbit #sc2004 (all from Santa Cruz Biotechnology); Cyclin 
D1 (SP4) #9104-S1 (rabbit antibody against human, mouse and rat proteins; NeoMarkers 
Inc.); PCNA #2586, (mouse antibody against human, mouse and rat proteins; Cell 
Signaling Inc.); Hif1α #07-628 (rabbit antibody against human protein; Upstate Inc.); 
BrdU #03-3900 (mouse antibody, species-independent; Zymed Laboratories). 
3.3.2 Mouse breeding and genotyping  
Mice with a deletion of the eNOS gene (Stock #2684) (Shesely et al., 1996) and 
control mice in the C57/BL6 background were obtained from Jackson Laboratory (Bar 
Harbor, ME), and exposed to a 12-hour light-dark cycle and fed tap water and regular 
chow at libitum. All procedures involving animals were approved by the University of 
Western Ontario Animal Care and Use Committee. All experiments were done using 
crosses of heterozygote mice to compare KO animals to wild type controls within litters. 
For PCR genotyping, tail snips were used to prepare DNA for PCR analysis. PCR 
genotyping was performed by simultaneous amplification of the eNOS wild type and null 
alleles as described (Hefler et al., 2001). PCR fragments were analyzed by agarose gel 
electrophoresis.  
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3.3.3 Skeletal staining and histology 
Animals were skinned, eviscerated and dehydrated in 95% ethanol overnight and 
then in acetone overnight. Skeletons were stained with 0.015% alcian blue, 0.05% 
alizarin red and 5% acetic acid in 70% ethanol for several days. Skeletons were then 
cleared in 1% KOH, passed through a decreasing KOH series and stored in 
glycerol/ethanol (1:1) (Wang et al., 2007). After dissection of mice, bones were rinsed 
with PBS, fixed in 4% Paraformaldehyde (PFA) overnight, placed in 10% formalin 
solution and sent for embedding and sectioning into 4µm sections at the Molecular 
Pathology Core Facility at the Robarts Research Institute (London, Ontario, Canada). 
Following sectioning, bones were stained with hematoxylin and eosin or safranin O/fast 
green using standard protocols (Solomon et al., 2009; Wang et al., 2007) or used for 
immunohistochemistry as described below. 
3.3.4 Immunohistochemistry and BrdU labeling 
For immunohistochemistry, sections unstained prior to use were incubated in 3% 
H2O2 for 15 min at room temperature, following by boiling for 20 min in 10 mM sodium 
citrate (pH 6.0) and blocking with 5% goat serum at room temperature for 30 min. 
Sections were incubated with primary antibody overnight at 4°C and secondary 
antibodies according to the manufacturers’ recommendations. After washing, the sections 
were incubated for 1-10 min with DAB substrate solution (Dako North America, Inc.), 
washed and mounted. All images were taken at room temperature with a Retiga EX 
camera connected to a Leica DMRA2 microscope using OpenLab 4.0.4 software. For cell 
counts in sections, all cells and cells positive for staining with primary antibody labeling 
were counted from three different areas of one section. Sections from at least three mice 
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per genotype, and at least three sections from every mouse, were analyzed, and averages 
and standard deviation from all counts/genotype are shown.  
For BrdU labeling, newborn mice were injected intraperitoneally with BrdU 
(Roche) at a dose of 0.03 mg/g body weight one hour before sacrifice. BrdU was detected 
in paraffin sections using anti-BrdU antibody (Zymed Laboratories) as described above. 
For all antibodies, negative controls were conducted following the same protocol in the 
absence of the primary antibody. 
3.3.5 Primary cell culture and MTT assays 
Tibiae, femuri and humeri were isolated from embryonic day 15.5 (E15.5) KO 
and control mouse using a Stemi DV4 Stereomicroscope (Zeiss). 20 bones from the same 
genotype were placed in 2ml α-MEM media (Invitrogen)/well containing 0.2% bovine 
serum albumin (BSA), 1 mM β-glycerophosphate, 0.05 mg/ml ascorbic acid and 
penicillin/streptomycin in a 6-well culture dish (Falcon), as described (James et al., 
2005). Then medium was removed and every 10-12 bones from each group placed in 1 
ml of 0.25% trypsin-EDTA (Invitrogen) for 15 min at 37°C. Trypsin was subsequently 
replaced with 1 mg/ml collagenase P (Roche) in DMEM/10% fetal bovine serum 
(Invitrogen), and cells were incubated at 37°C with rotation at 100 rpm for 90 min. 
Following digestion, the cell suspension was centrifuged for 5 min at 1000 rpm, and the 
collagenase containing supernatant was decanted. Chondrocytes were resuspended in 
medium containing 2:3 DMEM:F12, 10% fetal bovine serum, 0.5 mM L-glutamine, and 
penicillin/streptomycin (25 units/ml) supplemented with 0.25 mM ascorbic acid (Sigma) 
and 1 mM β-glycerophosphate (Sigma). Chondrocytes (10000 cell/ml) were seeded in 96-
well culture dish (Falcon), containing 100 µl of medium per well and cultured in the 
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presence of 5 % CO2. Cell numbers were determined by MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide) assay as described (Halawani et al., 2004; Wang et 
al., 2004). 
3.3.6 Tibia organ culture 
         Tibiae were isolated from E15.5 embryos from wild type and KO mice as described 
above (Agoston et al., 2007; Wang et al., 2007). Dissection day was considered to be day 
0 and tibiae were allowed to recover from dissection overnight in serum-free α-MEM 
medium 1 ml/well, 1 tibia/well containing 0.2% Bovine Serum Albumin (BSA), 0.5 mM 
L-glutamine, 40 units penicillin/mL and 40 μg streptomycin/mL in 24-well Falcon plates 
as described (Agoston et al., 2007; Wang et al., 2007). All culture dishes were maintained 
in an incubator containing 5% CO2. The following morning, bone length was measured 
using an eyepiece in the Stemi DV4 Stereomicroscope. Medium was changed every 48 
hrs beginning on day 1, and bones measured on days 2, 4 and 6. Results are expressed as 
growth in length relative to day 1. Experiments were repeated at least three times, with 4–
6 bones per treatment for each trial. 
3.3.7 Western blotting 
          Fresh cartilage from limbs of newborn mice was dissected in cold Puck's solution 
A (PSA; 80 g/l NaCl, 4.0 g/l KCl, 0.6 g/l KH2PO4, 0.9 g/l Na2HPO4·7H2O, and 10 g/l
 
glucose, pH 7.4). Modified Radioimmunoprecipitation (RIPA) Buffer extracts of 
cartilage were used directly for Western blotting (Appleton et al., 2007; Wang et al., 
2007). Blocking, incubation with antibodies and washing were carried out in accordance 
with instructions of the supplier of the primary antibody. Immunoblots were developed 
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using the ECL detection system (Amersham). Representative blots from three 
independent littermate comparisons are shown. 
3.3.8 RNA isolation, and real-time RT-PCR  
         Total RNA was isolated from epiphyseal cartilage of long bone from newborn mice 
using TRIzol (Invitrogen), according to the manufacturer's recommendations. Taqman 
real-time PCR was performed as described (James et al., 2005; Woods et al., 2005) with 
primers and probe sets from Applied Biosystems (Sox9 Mm00448840_m1; Col2a1 
Mm00491889_m1; Col10a1 Mm00487041_m1; Rora Mm00443103_m1; Hif1a 
Mm00468869_m1; Nos1 Mm00435175_m1; Nos2 Mm00440485_m1; Nos3 
Mm00435204_m1; Gapdh Mm99999915_g1).  Data were normalized to Gapdh mRNA 
levels and represent averages and SEM from direct comparison of mutant and control 
littermates from three different crosses. Statistical significance of real-time PCR results 
was determined by one way ANOVA with Bonferroni post-test using GraphPad Prism 
4.00 for Windows. 
3.3.9 Statistical analysis 
         All experiments were performed with at least three independent litters. Statistical 
significance was determined by a one-way ANOVA with Bonferroni post test using 
GraphPad Prism version 4.00 for Windows, GraphPad Software, San Diego, California, 
USA. 
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3.4 Results 
3.4.1 Inactivation of eNOS gene results in reduced viability and growth 
         We used eNOS-deficient mice to address the role of this gene in cartilage 
development in vivo. Based on our breeding protocol from heterozygote mice, Mendelian 
ratio would predict that 50% of newborn mice are heterozygote and 25% are homozygote 
eNOS null mice. However, examination of genotype distribution of newborn mice 
revealed that only 14% of pups are homozygous for the mutant eNOS allele, and 40% are 
heterozygous. Analyses of genotypes at different embryonic stages showed the expected 
Mendelian distribution (data not shown). These data suggest that loss of eNOS gene 
results in increased lethality at the late prenatal or the perinatal stage. Additionally, 
newborn eNOS-/- mice showed 44% neonatal death occurring shortly after birth. Slightly 
decreased body weight (86%) and length (92%) were found in eNOS-/- mice at birth. 
Analysis of both parameters over the first 42 days of life demonstrated that growth 
retardation became more pronounced in surviving eNOS-/- mice as the animals aged (Fig. 
3.1A). Growth retardation was similar in female and male mice (data not shown). 
However, some eNOS-/- mice demonstrated more severe delays in growth and 
development, and some were born with a kinky tail (6 out of 20 KO mice from 9 litters) 
(Fig. 3.1B).  
         We next examined the skeletal phenotype of eNOS-deficient mice. Whole skeletal 
staining with alcian blue and alizarin red confirmed that mutant mice have a smaller 
skeleton than control littermates at postnatal day 1 (Fig. 3.1C). The majority of mutant 
mice showed no obvious morphological changes in the skeleton. Detailed observation of  
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Figure 3.1 Loss of eNOS results in reduced growth.  
Body length and body weight of mice were determined during the first 42 days of their 
life. eNOS null mice show slower increases in both parameters compared to wild type 
littermates (A).  Mean and standard deviation from at least 8 mice per genotype are 
shown for each data point. (*P<0.05) (WT: wild type; KO: knockout). Comparison of an  
eNOS knockout (KO) mouse and a wild type (WT) littermate at postnatal day 4 
demonstrates delay in growth and development and a kinky tail in the mutant (B). Whole 
skeletal staining with alcian blue and alizarin red at postnatal day1 shows no 
morphological difference besides reduced size in mutants (C).  Measurements of selected 
individual bones confirm reduced bone length in humeri and tibiae in neonatal mutant 
mice (D). Real-time RT-PCR using RNA extracted directly from neonate cartilage from 
eNOS KO mice demonstrated upregulated nNOS transcript levels; iNOS mRNA levels 
did not change; and eNOS transcripts could not be detected in KO mice (E). (ND: not 
detectable; N = 4, *P<0.05).  
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the whole skeleton of mutant mice demonstrated a smaller rib cage and skull and a 
shorter appendicular skeleton. Measurement of selected individual bones confirmed 
reduced bone length of humeri (76%) and tibiae (80%) in neonatal mutant mice (Fig. 
3.1D). Real-time RT-PCR using RNA extracted directly from mutant neonate cartilage 
demonstrated upregulated nNOS transcription levels compared with control; iNOS 
mRNA levels were unchanged; and eNOS transcripts could not be detected in mutant 
mice, as expected (Fig. 3.1E).   
3.4.2 eNOS deficiency reduces chondrocyte proliferation in the growth plate  
      To elucidate the cellular basis for the reduced skeletal growth, we analyzed 
growth plate organization. Growth plates from newborn mutant mice displayed a similar 
chondrocyte arrangement in proliferative and hypertrophic zones as control animals (Fig. 
3.2A). Measurement of the width of the various growth plate zones showed that the 
proliferative zone is slightly smaller and the hypertrophic zone is slightly larger in KO 
growth plates, but these effects were not statistically significant (Fig. 3.2B). eNOS-/- 
growth plates were hypocellular (Fig. 3.2A). Counts of cell numbers in the proliferative 
zone of the growth plate revealed fewer cells per area in mutants (71% of control cell 
numbers), while cell counts in the epiphyseal cartilage did not show a significant 
difference between genotypes (Fig. 3.2C).  
We next asked whether changes in cell proliferation are the cause of 
hypocellularity in eNOS-deficient growth plates. BrdU incorporation assays showed a 
marked reduction in replicating cells in mutant mice that was confirmed by cell counts 
(Fig. 3.3A). Control experiments in these and all subsequent immunohistochemistry 
studies were done without primary antibody and showed no staining (data not shown).  
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Figure 3.2 eNOS deficiency results in reduced proliferating chondrocyte numbers in 
growth plate.  
Histological analyses (safranin O/Fast Green staining) demonstrate that growth plates 
from newborn mutant mice displayed a similar chondrocyte arrangement into 
proliferating and hypertrophic zones as control mice (A). Measurement of the width of 
the resting zone (RZ), proliferative zone (PZ) and hypertrophic zone (HZ) in the growth 
plates did not show significant changes in the mutant (B). However, cell numbers per 
area in the proliferative zone of the mutant growth plate are lower (71%) (C). (EC: 
epiphyseal cartilage; PZ: proliferative zone) (Scale bar=500µm) Mean and standard 
deviation from at least 8 mice per genotype are shown (*P<0.05). 
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Figure 3.3 eNOS deficiency reduces chondrocyte proliferation and endochondral 
bone growth in vitro. 
BrdU incorporation assays show a remarked reduction in replicating cells in eNOS 
mutant mice (A), which is confirmed by counting of labeled cells. Similarly, 
immunohistological staining of proliferating cell nuclear antigen (PCNA) showed 
reduced positive cell numbers per area in eNOS mutant mice (B). MTT assays 
demonstrate a slower increase in cell numbers of eNOS-/- primary chondrocytes than 
observed for cells from wild type or heterozygote littermates (C). In organ culture, 
mutant tibiae showed reduced bone growth compared with those from control animals at 
day 4 and day 6 of culture (D). (Scale bar=200µm) Mean and standard deviation from at 
least 4 independent experiments per genotype are shown (*P<0.05). 
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Immunohistochemical staining for proliferating cell nuclear antigen (PCNA) 
demonstrated a similar reduction in mutant mice (Fig. 3.3B). These data demonstrated 
reduced proliferation of chondrocytes upon loss of eNOS.  
          Because our mutant mice are eNOS-deficient in all cells of the body, it was 
possible that reduced bone growth and chondrocyte proliferation are secondary to loss of 
eNOS in other cell types. We therefore compared proliferation of primary chondrocytes 
from control and eNOS-/- mice in culture. MTT assays demonstrated that mutant cells 
increased their numbers more slowly than those form control littermates, while 
chondrocytes from heterozygote mice did not show any differences to wild type cells 
(Fig. 3.3C). In addition, we conducted organ culture experiments by growing tibiae from 
E15.5 eNOS-/- and wild type mice for 6 days in culture. While bones from both genotypes 
were of similar length at the beginning of the culture, mutant bones showed significantly 
reduced growth compared with those from control animals at day 4 and day 6 (Fig. 3.3D). 
These data suggest that eNOS is required for normal chondrocyte proliferation and 
endochondral bone growth in a cell-autonomous fashion. 
3.4.3 eNOS deficiency results in reduced cyclin D1 expression 
        To elucidate the reason for reduced cell numbers in eNOS-/- mice, we examined cell 
cycle protein expression in growth plates. Immunohistochemical staining of cyclin D1, 
which is required for normal chondrocyte proliferation (Beier, 2005; Beier et al., 2001), 
demonstrated reduced numbers of positive cells in mutant mice (Fig. 3.4A). Reduced 
cyclin D1 protein expression in eNOS-deficient cartilage was confirmed by western blot 
(Fig. 3.4B).  We recently described that the transcription factor ATF3 is upregulated  
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Figure 3.4 eNOS deficiency causes reduced cyclin D1 expression.  
Immunohistochemical staining for cyclin D1 showed reduced numbers of positive cells in 
eNOS null mice (A). Reduced cyclin D1 expression in mutants was confirmed by 
Western blot (B). In addition, activating transcript factor 3 (ATF3) was found 
upregulated in eNOS null mice by immunohistochemistry (C). Counting of the positive 
cells per area confirmed these changes in the mutant (D). (Scale bar=200µm) 
Representative pictures from at least 4 independent experiments are shown.  
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during chondrocyte hypertrophy and represses activity of the cyclin D1 promoter in 
chondrocyte (James et al., 2006). Immunohistochemistry demonstrated increased ATF3 
expression in eNOS-deficient growth plates (Fig. 3.4C), suggesting that premature 
induction of ATF3 expression in mutant mice leads to repression of cyclin D1 
transcription and chondrocyte proliferation. 
3.4.4 Premature differentiation of eNOS-deficient chondrocytes 
         Since reduced chondrocyte proliferation is often associated with premature cell 
cycle exit and maturation (Beier, 2005), we examined the expression of additional 
markers of prehypertrophic chondrocytes. Expression of the cell-cycle inhibitor p57, 
which promotes cell cycle exit and is required for normal chondrocyte differentiation, 
was found to be increased by immunohistochemistry (Fig. 3.5A) and Western blot (Fig. 
3.5B) in mutant mice. In wild type growth plates, p57 protein is restricted to a small band 
of prehypertrophic chondrocytes, while in KOs there is both earlier staining in late 
proliferative cells and sustained staining in hypertrophic chondrocytes.  The nuclear 
receptor RORα is another marker for prehypertrophic and hypertrophic chondrocytes 
(Woods et al., 2009b) that showed a similar expansion in expression as p57 in mutant 
mice (Fig. 3.5C). Similar upregulation was observed for Hif-1α (Fig. 3.5D), a sensor for 
low oxygen tension (Hwang et al., 1988; Koshiji and Huang, 2004) that has been 
implicated in cartilage development (Schipani et al., 2001). 
3.4.5 eNOS deficiency changes cartilage-specific gene expression  
         We sought to complement our immunohistochemistry results by quantitative 
analyses of gene expression, using real-time RT-PCR of RNA directly extracted from  
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Figure 3.5 Premature differentiation of eNOS-deficient chondrocytes.  
Immunohistochemistry demonstrates increased expression of the cell-cycle inhibitor 
protein p57 in mutant mice (A), which is confirmed by Western blot (B). The expression 
of prehypertrophic and hypertrophic markers retinoic acid related orphan receptor alpha 
(RORα) and hypoxia inducible factor 1 alpha (Hif-1α) is also upregulated in mutant 
growth plates, as shown by immunohistochemistry (C and D). Counting of the positive 
cells per area confirmed these changes in the mutant (E). (Scale bar=200µm) 
Representative pictures from at least 4 independent experiments are shown. 
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cartilage. Our results revealed decreased expression of early chondrocyte markers, 
Col2a1 and Sox9 and increased expression of the prehypertrophic markers RORa and 
Hif1a (Fig. 3.6). In contrast, transcript levels for Col10a1, a marker of fully hypertrophic 
chondrocytes, were only elevated slightly (non-significantly) in mutant cells. These data 
suggest that the major phenotype in eNOS-deficient growth plates is the premature exit 
from the cell cycle and earlier prehypertrophic differentiation, with fewer effects on 
terminal differentiation. 
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Figure 3.6 eNOS deficiency promotes prehypertrophic gene expression.  
Real-time RT-PCR analyses with RNA extracted directly from neonate cartilage reveals 
decreased expression of the early chondrocytes markers Col2a1 and Sox9, and increased 
expression of prehypertrophic markers RORα and Hif1a in eNOS-deficient cartilage, 
while expression of the hypertrophic marker Col10a1 was not significantly changed. 
Mean and standard deviation from at least 4 independent experiments per genotype are 
shown (*P<0.05). 
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3.5 Discussion  
      While NO has been shown to play an important role in controlling chondrocyte 
physiology in OA, the roles of the three NOS enzymes in cartilage development are less 
clear. In this study, we provide evidence for an important function of eNOS in the 
regulation of chondrocyte proliferation and differentiation. Our data show that genetic 
ablation of the eNOS gene in vivo results in reduced chondrocyte proliferation and 
endochondral bone growth. Analyses of the underlying molecular mechanisms suggest 
that these effects are likely due to altered expression of several cell-cycle proteins and the 
modulation of intracellular pathways with known roles in chondrocyte differentiation, 
including Sox 9 and Hif-1α.   
      Although there were no gross morphological changes in the axial and appendicular 
skeleton of mutant mice, staining confirmed smaller rib cages, skull, spine and shorter 
long bones. Some KO mice showed more pronounced growth retardation and other 
defects such as kinky tails. The reasons for the variability in the phenotype are not 
known, but are consistent with earlier reports (Hefler et al., 2001).  eNOS-deficient mice 
share some  similarities to those observed in mice that lack C–type natriuretic peptide 
(CNP) (Chusho et al., 2001), especially dwarfism and a reduction in chondrocyte 
proliferation. Because both NO and CNP stimulate the production of cGMP via soluble 
or particulate guanylyl cyclases (GC) (Teixeira et al., 2008), these similarities are not 
surprising and provide further evidence for the importance of cGMP signaling in 
endochondral bone formation.  However, the phenotype of eNOS null mice does not 
exactly resemble that of mice lacking CNP or the main effector of cGMP in cartilage, 
cGMP-dependent kinase II (cGKII) (Pfeifer et al., 1996). For example, mice lacking CNP 
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have strikingly narrow growth plates and shorter proliferating and hypertrophic zones 
(Chusho et al., 2001), which we did not see in our mutant mice. Because NO is produced 
through different NOS isoforms, deletion of eNOS might be compensated by the other 
two NOS enzymes. Indeed, we found a 2-fold upregulation of nNOS transcript levels in 
eNOS deficient mice, suggesting that these two constitutive forms have partially 
redundant roles in cartilage. Additionally, cGMP is not the only downstream target of 
NO; for example, NO can alter the activity of several proteins though tyrosine 
nitrosylation (Foster et al., 2009; Hess et al., 2005), which could account for some of the 
observed differences to CNP- and cGKII-deficient mice.  
A requirement for eNOS in proliferation has been described for a number of cells, 
including endothelial cells and osteoblasts (Aguirre et al., 2001; Beier et al., 1999b). On 
the other hand, Teixeira and colleagues had reported that NO signaling stimulates 
chondrocyte hypertrophy in chicken chondrocytes (Teixeira et al., 2005), raising the 
question whether loss of eNOS would promote proliferation at the expense of 
differentiation or result in the opposite phenotype, e.g. reduced proliferation and earlier 
onset of maturation. Our results clearly support the latter model. While species-specific 
effects or differences in approaches (e.g. in vivo versus in vitro) could explain some of 
the differences between our study and Teixeira’s (Teixeira et al., 2005), the more likely 
explanation is that NO effects in chondrocytes are differentiation stage- and 
concentration-dependent. For example, it is plausible to speculate that loss of only one 
NOS protein has different effects as pharmacological inhibition of all three.  
         eNOS inactivation results in reduced chondrocyte proliferation in vivo and in vitro. 
Considering that eNOS was deleted in all cells of the body in our mice, it was unclear 
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whether the reduced chondrocyte proliferation is because of loss of eNOS in cartilage or 
secondary to defects in other tissues (e.g. in endocrine tissues or endothelial cells). 
Therefore, we conducted organ culture and primary cell culture in vitro, thus removing 
systemic and endocrine influences. Our organ culture data demonstrated reduced tibia 
growth upon loss of eNOS, and mutant chondrocytes showed reduced multiplication of 
cells in culture. While these culture systems contain perichondral and periosteal cells that 
might be responsible for some of the observed changes, these results are consistent with 
the in vivo phenotype of eNOS KO mice and a cell-autonomous role of eNOS in 
chondrocyte proliferation.         
         The progression of the eukaryotic cell cycle is controlled by cyclins and cyclin-
dependent kinases (Beier, 2005). For example, cyclin D1 has been shown to regulate the 
G1 phase of the cell cycle, is expressed specifically in the proliferating zone of growth 
plates and required for maximal chondrocyte proliferation in vivo and in vitro (Beier, 
2005; Beier et al., 2001). Our data showed a decline in cyclin D1 and an increase in p57 
expression, presumably resulting in slower cell-cycle progression and early cell-cycle 
exit upon loss of eNOS. The earlier cell cycle exit and resulting acceleration in the onset 
of prehypertrophic differentiation is also supported by increased expression of 
prehypertrophic markers such as RORα and Hif-1α, and by reduced expression of 
markers for proliferating chondrocytes, such as collagen II and Sox9. Of note, growth 
plate zone measurements and analyses of type X collagen expression suggest that eNOS 
deficiency accelerates prehypertrophic differentiation without accompanying acceleration 
of terminal hypertrophic differentiation.   
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In summary, our data demonstrate a role for eNOS in chondrocyte proliferation 
and endochondral bone growth. Loss of eNOS affects numerous aspects of cartilage 
physiology, including chondrocyte proliferation and gene expression. Further 
investigations into the specific mechanisms involved will result in a better understanding 
of physiological and pathological ossification and the role of eNOS in arthritic diseases.  
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CHAPTER FOUR 
 
 
 
REDUCED CHONDROCYTE PROLIFERATION INCREASED APOPTOSIS 
AND PREMATURE DIFFERENTIATION IN NEURONAL NITRIC OXIDE 
SYNTHASE DEFICIENT MICE* 
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Yan, Q., Feng, Q. and Beier, F. Reduced chondrocyte proliferation increased apoptosis 
and premature differentiation in neuronal nitric oxide synthase-deficient mice. 
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4.1 Chapter summary 
        Nitric oxide (NO) has been implicated in the local regulation of bone metabolism. 
However, the contribution made by specific nitric oxide synthase (NOS) enzymes to 
skeletal development is unclear. The objective of this study was to examine the effects of 
inactivation of neuronal nitric oxide synthase (nNOS) on cartilage development in mice.  
Mice carrying a null mutation in the nNOS gene were used in this study to address our 
objectives. Histological staining, immunohistochemistry and in situ analyses were 
employed along with real-time RT-PCR. nNOS-null mice show transient growth 
retardation and shorter long bones. nNOS-deficient growth plates are hypocellular, with a 
marked reduction in replicating cells. Reduced chondrocyte numbers may in part be due 
to premature cell-cycle exit because of decreased cyclin D1 and increased p57 
expressions in mutants. In addition, apoptosis was increased as shown by increased 
cleaved-caspase 3 staining in terminal hypertrophic chondrocytes in mutants. Expression 
of early chondrocyte markers such as Sox genes was reduced in mutant mice, while 
expression of prehypertrophic markers Rorα and c-Fos was increased. Histological 
sections also demonstrated thinner cortical bone and fewer trabeculae in mutant mice. 
These data identify an important role of nNOS in chondrocyte proliferation and 
endochondral bone growth and demonstrate that nNOS coordinates cell-cycle exit and 
chondrocyte differentiation in cartilage development.  
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4.2 Introduction 
       NO is a small signaling molecule with important regulatory effects in many tissues. 
It can function as an intracellular messenger, an autacoid, a paracrine substance, or a 
neurotransmitter (Murad, 1999). The versatile functions of NO stem from the chemical 
properties of the compound. NO is a gaseous uncharged free radical with an unshared 
electron that makes it easy to react with many molecules and proteins to regulate 
biological processes (Moncada et al., 1991). Because it is uncharged, it can freely diffuse 
to the surrounding cells, making it ideal as a signaling molecule (Teixeira et al., 2008). In 
most processes, NO activates soluble guanylyl cyclase, resulting in increased levels of the 
intracellular secondary messenger cGMP (Moncada et al., 1991; Murad, 1999), but other 
modes of signaling such as protein nitrosylation also contribute to the biological effects 
of NO (Ignarro, 1999; Moncada et al., 1991). Different cells and tissues have different 
abilities to produce NO. In general, low levels of NO are produced from constitutive 
nitric oxide synthases (endothelial NOS/eNOS and neuronal NOS/nNOS) and high levels 
of NO stem from inducible nitric oxide synthase (iNOS). The ultimate effects of NO are 
determined by its concentration, its source, and molecules in the microenvironment that it 
can react with. Over years NO has been known to regulate bone cell metabolism, bone 
remodeling and chondrocyte physiology in osteoarthritis (OA) (Abramson, 2008; 
Teixeira et al., 2008; van't Hof and Ralston, 2001), but the contributions made by specific 
NO synthase (NOS) enzymes to bone growth and development are unclear (Collin-
Osdoby et al., 1995; Teixeira et al., 2005).  In light of the prevalent connections between 
chondrocyte differentiation and the pathogenesis of OA (Drissi et al., 2005), and the well-
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known roles of NO in OA,  the elucidation of the role of individual NOS genes in 
cartilage development is of great importance. 
          Formation of the skeleton is achieved through two independent mechanisms: 
intramembranous and endochondral ossification (Karsenty, 2003; Kronenberg, 2003). 
Endochondral bone formation is a precisely regulated process and responsible for the 
formation of most bones in the adult skeleton. It involves the steps of chondrogenesis, 
chondrocyte proliferation, differentiation, and hypertrophy and eventually replacement of 
cartilage tissue by bone tissue and bone marrow (Beier, 2005; Horton, 2003; Karsenty 
and Wagner, 2002; Kronenberg, 2003; Provot and Schipani, 2005; Teixeira et al., 2008). 
During postnatal development, proliferation and hypertrophy occur in a controlled 
fashion in the cartilage growth plate that determines the final length of the adult bone. 
Within the growth plate, chondrocytes are organized in distinguished zones (resting, 
proliferating, prehypertrophic and hypertrophic zones) based on their morphologic shapes 
and gene expression patterns (Beier, 2005). If any steps during this process are not 
properly regulated, skeletal diseases will result, such as different types of 
chondrodysplasias (Zelzer and Olsen, 2003).  
          We recently described cartilage development in eNOS-deficient mice that display 
reduced bone growth (Yan et al., 2010). This effect appears to be due to a chondrocyte-
autonomous role of eNOS in chondrocyte proliferation. However, nNOS mRNA levels 
were upregulated in eNOS-null chondrocytes, suggesting that nNOS partially 
compensates for the loss of eNOS. nNOS KO mice have been found to be viable, have 
enlarged stomachs due to pyloric muscle hypertrophy, exhibit insulin resistance and 
resistance to neural damage as the result of stroke induced by middle cerebral artery 
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ligation (van't Hof et al., 2004). nNOS expression has been detected during skeletal 
development and fracture healing, and previous studies showed reduced bone remodeling 
with a significant reduction in osteoblast and osteoclast numbers in nNOS-deficient mice 
(van't Hof et al., 2004).  However, the exact mechanisms and functions of nNOS in 
earlier stages of skeletal development have not been described. In this study, we 
investigated the effects of nNOS deficiency on cartilage development and endochondral 
bone formation. 
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4.3 Materials and methods 
4.3.1 Antibodies and reagents 
         All reagent materials and general chemicals were obtained from Invitrogen, Sigma 
or VWR unless otherwise stated. The following antibodies were employed in this study: 
Kip2/p57 #sc8298 (rabbit antibody against human protein), RORα #sc28612 (rabbit 
antibody against human protein), ATF3 #sc188 (rabbit antibody against human protein), 
Sox9 #sc-17340 (goat antibody against human protein), c-Fos #sc-52 (rabbit antibody 
against human protein), Goat-anti-mouse #sc2005, Goat-anti-rabbit #sc2004 (all from 
Santa Cruz Biotechnology); Cyclin D1 (SP4) #9104-S1 (rabbit antibody against human, 
mouse and rat proteins; NeoMarkers Inc.); PCNA #2586, (mouse antibody against 
human, mouse and rat proteins; Cell Signaling Inc.).  
4.3.2 Mouse breeding and genotyping 
         Mice with a deletion of the nNOS gene (Stock #2986) and control mice in the 
C57/BL6 background were obtained from Jackson Laboratory (Bar Harbor, ME), and 
exposed to a 12-hour light-dark cycle and fed tap water and regular chow at libitum (van't 
Hof et al., 2004). All procedures involving animals were approved by the University of 
Western Ontario Animal Care and Use Committee. For PCR genotyping, tail snips were 
used to prepare DNA for PCR analysis. PCR genotyping was performed by simultaneous 
amplification of the wild type and null nNOS alleles as described (Drissi et al., 2005; 
van't Hof et al., 2004). PCR fragments were analyzed by agarose gel electrophoresis.   
4.3.3 Histology and Immunohistochemistry  
          After dissection of mice, bones were rinsed with PBS, fixed in 4% 
paraformaldehyde (PFA) overnight, placed in 10% formalin solution and sent for 
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embedding and sectioning into 4µm sections at the Molecular Pathology Core Facility at 
the Robarts Research Institute (London, Ontario, Canada). Following sectioning, bones 
were stained with hematoxylin and eosin or safranin O/fast green using standard 
protocols (Solomon et al., 2009; Wang et al., 2007) or used for immunohistochemistry as 
described below. 
         For immunohistochemistry, sections unstained prior to use were dewaxed and 
incubated in 3% H2O2 for 15 min at room temperature, followed by boiling for 20 min in 
10 mM sodium citrate (pH 6.0) and blocking with 5% goat serum at room temperature for 
30 min. Sections were incubated with primary antibody overnight at 4°C and secondary 
antibodies according to the manufacturers’ recommendations. After washing, sections 
were incubated for 1-10 min with DAB (3,3′ -diaminobenzidine tetrahydrachloride) 
substrate solution (Dako North America, Inc.), washed and mounted. All images were 
taken at room temperature with a Retiga EX camera connected to a Leica DMRA2 
microscope using OpenLab 4.0.4 software. For cell counts in sections, all cells and cells 
positive for staining with primary antibody labeling were counted from three different 
areas of one section. Sections from at least three mice per genotype, and at least three 
sections from every mouse, were analyzed, and averages and standard deviation from all 
counts/genotype are shown.  
4.3.4 RNA isolation and real-time RT-PCR  
         Total RNA was isolated from epiphyseal cartilage of long bone from newborn mice 
using TRIzol (Invitrogen), according to the manufacturer's recommendations. Taqman 
real-time PCR was performed as described (Agoston et al., 2007; Woods et al., 2005) 
with primers and probe sets from Applied Biosystems (Sox5 Mm00488381_m1; Sox6 
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Mm00488393_m1; Sox9 Mm00448840_m1; P57 Mm00438170_m1; MMP13 
Mm00439495_m1; Igf1 Mm00439560_m1; Gapdh Mm99999915_g1). Data were 
normalized to Gapdh mRNA levels and represent averages and SEM from direct 
comparison of mutant and control littermates from three different crosses.  
4.3.5 Statistical analysis 
         All experiments were performed with at least three independent litters. Statistical 
significance was determined by a one-way ANOVA with Bonferroni post test using 
GraphPad Prism version 4.00 for Windows, GraphPad Software, San Diego, California, 
USA. 
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4.4 Results 
4.4.1 Inactivation of nNOS gene results in reduced bone length 
         We used nNOS-deficient mice to address the role of this gene in cartilage 
development in vivo.  The knockout mice were viable and fertile, and the general 
appearance of stature and gait were unremarkable, but male knockout mice appeared 
more aggressive. Body weight and length were not significantly changed in nNOS-/- mice 
at birth. Growth retardation developed in surviving nNOS-/- mice in the postnatal period at 
day 21 to 42, as shown by reduced body weight and length (Fig. 4.1A). Body weight 
showed significant reduction at postnatal day 11, before body length was reduced (Fig. 
4.1A). However, analyses at 3 month and 1 year of age demonstrated similar body weight 
and body length between genotypes (data not shown), suggesting that KO mice catch up 
during ageing. Observation of alcian blue/alizarin red-stained skeletons showed no 
obvious morphological changes in the axial and appendicular skeleton of mutants (data 
not shown), but measurement of selected individual bones confirmed reduced bone length 
in tibiae and humerus in mutant mice at postnatal day 21 (Fig. 4.1B).  
4.4.2 nNOS deficiency results in reduced chondrocyte proliferation in the growth 
plate  
         To elucidate the cellular basis for the skeletal phenotype, we analyzed growth plate 
organization at different developmental stages. Growth plates from newborn mutant mice 
displayed a similar chondrocyte arrangement in resting, proliferative and hypertrophic 
zones as control mice (Fig. 4.2A). Measurement of the lengths of resting, proliferating 
and hypertrophic zones did not show significant differences (data not shown) between 
genotypes, and cells in the resting and hypertrophic zones of nNOS null mice did not 
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Figure 4.1 Loss of nNOS results in reduced growth and bone length.  
Analyses of body weight and length of wild type and nNOS homozygote null mice 
showed that growth retardation developed in nNOS null mice during the first 42 days of 
their life (A).  Measurement of selected individual bones confirmed reduced bone length 
in humerus and tibiae in postnatal day 21 mutant mice (B). Mean and standard deviation 
from at least 8 mice per genotype are shown for each data point. (*P<0.05) (WT: wild 
type; KO: knockout).  
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Figure  4.2 Lack of nNOS causes reduced numbers of proliferating chondrocytes.  
Safranin O/Fast Green staining of tibia growth plate sections from newborn mice 
demonstrated similar growth plate architecture in both genotypes, however, counting of 
cells revealed fewer cells in the proliferative zone of mutant growth plates (A and B). 
Detailed analyses of H&E stained cells in the resting, proliferative, and hypertrophic 
zones confirmed that the major differences occur in the proliferative zone (C). (RC: 
resting cells; PC: proliferating cells; HC: hypertrophic cells). (Scale bar=200µm) Mean 
and standard deviation from at least 6 mice per genotype are shown (*P<0.05). 
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appear markedly different from controls. However, nNOS-/- growth plates were 
hypocellular, especially in the proliferative zone in the center of the growth plates. Some 
cells appear to be smaller in size, and the proliferative zone was disorganized with fewer 
and shorter columns (Fig. 4.2A,B and C).  Counts of cell numbers in the proliferative 
zone of the growth plate revealed fewer cells in mutants (73% of control cell numbers per 
area) (Fig. 4.2B).  
Since our mutant mice showed lower cell numbers in the proliferative zone of the 
growth plate, we next examined chondrocyte proliferation and apoptosis. 
Immunohistochemical staining for proliferating cell nuclear antigen (PCNA) 
demonstrated a reduction in positive cells in mutant mice (Fig. 4.3A). Reduced cell 
counts could also be due to increased cell apoptosis, which we examined by 
immunohistochemical staining for cleaved (activated) caspase 3. Staining for cleaved 
caspase 3 was increased in hypertrophic chondrocytes of mutant mice (Fig. 4.3B).  
            To elucidate the reason for reduced proliferation in nNOS-/- mice, we examined 
cell cycle protein expression in growth plates. Immunohistochemical staining for cyclin 
D1, which controls progression through the G1 phase of the cell cycle (Beier, 2005), 
demonstrated reduced number of positive cells in mutant mice (Fig. 4.3C). The 
transcription factor ATF3 acts as a repressor of cyclin D1 transcription in chondrocytes 
(James et al., 2006). Immunohistochemistry demonstrated a larger number of ATF3-
expressing chondrocytes in nNOS-deficient growth plates (Fig. 4.3D), suggesting that 
premature induction of ATF3 expression in mutant mice leads to repression of cyclin D1 
transcription and chondrocyte proliferation.  
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Figure 4.3 nNOS deficiency reduces chondrocyte proliferation and increases 
apoptosis.  
Immunohistochemical staining of newborn tibia sections for proliferating cell nuclear 
antigen (PCNA; A) or cyclin D1 (C) showed a reduction in stained cells in mutant mice. 
Increased staining for cleaved caspase 3 was found in hypertrophic chondrocytes in 
mutant tibia sections (B). In addition, expression of ATF3 protein was increased in 
growth plates from newborn mutant mice (D). (Scale bar=200µm) Representative 
pictures from at least 3 independent experiments are shown. Mean and standard deviation 
from at least 6 mice per genotype are shown (*P<0.05). 
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4.4.3 nNOS-deficient chondrocytes differentiate prematurely 
         Since reduced chondrocyte proliferation is often associated with premature cell 
cycle exit and maturation (Beier, 2005), we examined the expression of additional 
markers of prehypertrophic chondrocytes. Expression of the cell-cycle inhibitor p57, 
which promotes cell cycle exit and is required for normal chondrocyte differentiation, 
was found increased by immunohistochemistry in mutant mice (Fig. 4.4A). 
Immunohistochemistry also showed a similar increase in the number of cells expressing 
the transcription factors c-Fos (Fig. 4.4B) and RORα (Fig. 4.4C), both of which have 
been implicated in hypertrophic chondrocyte-specific gene expression (Riemer et al., 
2002; Woods et al., 2009a). In contrast, Hif-1α protein expression was not changed in 
KO mice (Fig. 4.4D).  
4.4.4 nNOS deficiency affects cartilage-specific gene expression  
         In parallel, we analyzed expression of several cartilage marker genes in the mutant 
mice by real-time RT-PCR, using RNA directly extracted from cartilage. Our results 
revealed decreased expression for early chondrocyte markers Sox5 and Sox6 (Fig. 4.5A, 
B) while the reduction in mRNA levels for Sox9 did not reveal statistical significance 
(Fig. 4.5C). Real-time RT-PCR also demonstrated increased expression of 
prehypertrophic and hypertrophic markers p57 and Mmp13 (Fig. 4.5D,E). Transcript 
levels for Igf1, which plays an important role in regulating skeletal development and bone 
remodeling (Wang et al., 1992), were also strongly decreased in the mutant mice (Fig. 
4.5F). Transcript levels for several other genes did not show significant responses to 
disruption of the nNOS gene in cartilage, including Ihh, aggrecan, Col 10a1, Vegfa, 
Runx2, and RANKL (data not shown). 
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Figure 4.4 Premature differentiation of nNOS-deficient chondrocyte 
Expression of the cell-cycle inhibitor p57, which promotes cell cycle exit and is required 
for normal chondrocyte differentiation, was found increased by immunohistochemical 
analyses of newborn tibia sections in mutant mice (A). Immunohistochemistry also 
showed a similar increase in the number of cells expressing the transcription factors c-
Fos (B) and RORα (C), while Hif1α expression did not change in the mutant mice (D) 
from newborn tibia sections. (Scale bar=200µm) Representative pictures from at least 3 
independent experiments are shown. 
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Figure 4.5 nNOS deficiency affects cartilage-specific gene expression.  
Real-time RT-PCR revealed decreased expression for early chondrocyte markers Sox5 
and Sox6 (A, B). And increased expression of the prehypertrophic and hypertrophic 
markers p57 and MMP13 were also demonstrated in cartilage of KO mice (C,D). 
Transcript level for Igf1 was significantly decreased in the mutant mice (E). mRNA 
levels of iNOS and eNOS were also found upregulated in nNOS KO cartilage (F,G). 
Mean and standard deviation from at least 4 independent experiments per genotype are 
shown (*P<0.05). 
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Interestingly, we also demonstrated upregulated eNOS and iNOS mRNA levels in the 
nNOS KO samples (Fig. 4.5G,H).   
4.4.5 Loss of nNOS results in reduced trabecular bone and calcium deposition 
         To analyze whether nNOS deficiency had effects on endochondral ossification, we 
next examined trabecular bone formation and ossification patterns in mutant mice. Von 
Kossa staining demonstrated mineralization of trabecular and cortical bone in tibia 
sections from postnatal day 21 mice, which was clearly decreased in mutant mice (Fig. 
4.6A). A lack of trabecular structures was seen by picrosirius red staining for fibrillar 
collagen (Fig. 4.6B), suggesting that these effects are not simply due to delayed 
mineralization, but to a delay or reduction in bone formation. Additionally, thinner 
cortical bone was also shown in mutant mice by Safranin O/Fast green staining from 
postnatal day 12 mice (Fig. 4.6C). Secondary ossification centers were advanced in 
control mice at postnatal day 12, but age-matched KO mice displayed underdeveloped 
ossification centers (Fig. 4.6D).  
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Figure 4.6 Deficient of nNOS leads to reduced trabecular bone and calcium 
deposition. 
Mineralization of trabecular and cortical bone shown by VonKossa staining in tibia 
sections from postnatal day 21 mice was clearly decreased in mutant mice (A). A similar 
lack of trabecular structures was also seen by picrosirius red staining for fibrillar collagen 
(B). Additionally, thinner cortical bone was also showed in mutant mice by Safranin O/ 
Fast green staining (C) from postnatal day 12 mice tibiae. Secondary ossification centers 
were advanced in control mice at postnatal day 12, but displayed underdeveloped 
ossification centers in mutant mice (D). (Scale bar: 200µm for A,B,D; 50µm for C) 
Representative pictures from at least 3 independent experiments are shown. 
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4.5 Discussion  
        The signaling pathways that control growth plate chondrocyte proliferation and 
differentiation during endochondral ossification are incompletely understood.  In this 
study, we provide evidence for an important role of the nNOS gene in these processes. 
Our data show that genetic ablation of nNOS results in reduced chondrocyte proliferation 
and endochondral bone growth in vivo. Analyses of these changes in cellular and 
molecular levels suggest that these effects are likely due to altered expression of several 
cell-cycle proteins, such as cyclin D 1 and p57, as well as modulation of other genes with 
known roles in cartilage differentiation, including Sox genes, RORα and c-Fos.   
        Although there were no obvious morphological changes in the axial and 
appendicular skeleton, measurement of individual bones confirmed shorter tibiae and 
femurs in postnatal day 21 mutant mice. Detailed analyses of nNOS null tissue sections 
revealed several abnormalities, most notably reduced chondrocyte proliferation. nNOS-
deficient growth plates resemble those we observed in mice lacking the eNOS gene (Yan 
et al., 2010) and also share similarities to those in mice deficient for C-type natriuretic 
peptide (CNP) (Chusho et al., 2001). Because both NO and CNP stimulate the production 
of cGMP via soluble or particulate guanylyl cyclases (GC) (Chusho et al., 2001), these 
similarities are not surprising and further document the importance of cGMP signaling in 
endochondral bone formation. However, it should be noted that a major phenotype of 
CNP null mice is a reduction in the length of the hypertrophic zone  (Chusho et al., 2001) 
that we did not observe here. One potential explanation for this difference is that during 
hypertrophy, when all three NOS genes are expressed highly (Teixeira et al., 2005), 
144 
 
eNOS and/or iNOS (or potentially CNP) can compensate for the loss of nNOS, while 
they are not able to do so in the proliferating zone.  
          The growth plate phenotype of nNOS KO mice is strikingly similar to that of 
eNOS null mice (Yan et al., 2010). Given the similar functions of eNOS and nNOS, the 
similarities between the phenotypes of both KO lines are not surprising. The 
compensatory upregulation of transcripts for both enzymes in the eNOS and nNOS KO 
mice provides further evidence for overlapping function of the two genes. It is likely that 
simultaneous inactivation of both genes would have more severe outcomes, but we have 
not been able to obtain double KO mice despite extensive efforts. However, it should be 
noted that mice lacking all 3 NOS genes have been described (Sabanai et al., 2008). Even 
though those mice show a very high rate of lethality (85%), the surviving triple NOS 
knockout mice live a surprisingly normal life (Nakata et al., 2008), suggesting that 
additional compensatory mechanisms may exist.  
nNOS inactivation, very similar to deletion of the eNOS gene (Yan et al., 2010),  
results in reduced chondrocyte proliferation and increased apoptosis. However, increased 
staining for active caspase 3 mainly located to terminally differentiated hypertrophic 
chondrocytes, suggesting that apoptosis plays no or only a minor role in the 
hypocellularity that we observed mainly in the proliferative zone.   
One of the major reasons for the reduced proliferation appears to be the induction 
of the transcription factor ATF3, which is able to suppresses cyclin D1 transcription 
(James et al., 2006). Cyclin D1 expression is induced by many mitogenic stimuli and 
pathways in chondrocytes (Beier, 2005). Our studies suggest that in addition to positive 
regulation through transcription factors such as ATF2 and CREB (Beier et al., 2001; 
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Beier et al., 1999b; Beier and LuValle, 2002), cyclin D1 transcription is also under 
negative regulation by ATF3 (James et al., 2006), for example in response to reduced NO 
levels. The cyclin-dependent kinase inhibitor p57 is a second cell cycle protein showing 
altered expression in the absence of eNOS or nNOS. Immunohistochemsitry showed 
earlier and broader expression in mutant mice, along with other prehypertrophic markers 
such as RORα. At the moment, we don’t know whether NO signaling regulates cyclin D1 
and p57 expression through a common pathway or through different effectors. It is also 
possible that premature differentiation to prehypertrophic chondrocytes is due to the 
reduced expression of Sox5, Sox6 and potentially Sox9 in nNOS KO cartilage, but the 
relationship between these transcription factors and cyclin D1 expression has not been 
addressed. Finally, reduced expression of Igf1 could also contribute to the dwarf 
phenotype of nNOS KO mice, although the reduced growth in Igf1-deficient mice is 
largely due to smaller size of hypertrophic chondrocytes, as opposed to the primary effect 
on cell proliferation in our mice (Wang et al., 2006). 
 Loss of nNOS results in reduced von Kossa staining of cortical and trabecular 
bone. Picrosirius red staining suggests that this effect is due to paucity of trabecular 
structures per se, not just a delay in mineralization.  At the moment, it is unclear whether 
this phenotype is secondary to defects in cartilage development or due to intrinsic 
functions of nNOS in osteoblasts or osteoclasts. As has been shown before (van't Hof et 
al., 2004), the similar phenotypes between trabecular and cortical bone (which does not 
develop from a cartilage intermediate) suggest the latter, but cell type-specific KO 
models will be required to resolve this question. 
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In summary, our data demonstrate a role for nNOS in chondrocyte proliferation 
apoptosis and maturation. Loss of nNOS affects numerous aspects of cartilage 
physiology, including chondrocyte proliferation and gene expression, as well as 
mineralization of bone. It appears likely that the overall phenotype of nNOS deficient 
mice is a combination of alternations in all these aspects. Further investigations into the 
specific mechanisms involved will result in a better understanding of physiological and 
pathological skeletal development and associated diseases, such as osteoarthritis and 
osteoporosis.  
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5.1 Overview of the research project 
         The focus of this thesis was to investigate the role of NOS/NO signaling in 
endochondral bone formation. The roles of NO and NOS genes have been studied 
extensively in bone remodeling and arthritis (Abramson, 2008; Scher et al., 2007; van't 
Hof and Ralston, 2001). This pathway has also been implicated in chondrocyte 
physiology during development.  Teixeira and colleagues had shown that excess NO 
promotes hypertrophic differentiation and apoptosis of chondrocytes in chicken (Teixeira 
et al., 2005; Teixeira et al., 2001). However, much less is known about the specific roles 
of individual NOS genes in cartilage development and endochondral ossification 
(Teixeira et al., 2008).  
          Endochondral bone formation is a precisely regulated process, involving the steps 
of chondrogenesis, chondrocyte proliferation, differentiation, hypertrophy and eventually 
replacement of cartilage tissue by bone tissue and bone marrow (Beier, 2005; Horton, 
2003; Karsenty and Wagner, 2002; Kronenberg, 2003; Provot and Schipani, 2005; 
Teixeira et al., 2008). If any steps during this process are not properly regulated, skeletal 
diseases will result, such as different types of chondrodysplasias (Zelzer and Olsen, 
2003). Therefore, it is important to investigate the cellular mechanisms controlling 
growth plate regulation, for a better understanding of pathophysiological processes 
resulting in skeletal diseases. 
           The intracellular signaling pathways that control growth plate chondrocyte 
proliferation and differentiation during endochondral ossification are incompletely 
understood. Over the last several years, our studies in the laboratory have already 
identified Rac1 gene as an important regulator of chondrocyte differentiation in vitro and 
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in vivo (Wang et al., 2007; Woods et al., 2007b). In particular, mice with cartilage-
specific deletion of the Rac1 gene display high mortality, profound dwarfism and 
numerous skeletal defects (Wang et al., 2007). The severe dwarfism we observed upon 
cartilage-specific deletion of Rac1 gene is mostly due to the profound reduction in 
chondrocyte proliferation (Wang et al., 2007; Woods et al., 2007b). However, the 
downstream mechanisms connecting Rac1 to chondrocyte proliferation are unknown.  
         Rac1 has been shown to control many cellular processes, including actin dynamics, 
gene expression and generation of reactive oxygen species (ROS) (Bustelo et al., 2007; 
Hordijk, 2006). The first thought during this project was to indentify whether ROS 
signaling mediates Rac1 effects on chondrocyte proliferation. However, a recent study 
showed that elevated ROS levels inhibit chondrocyte proliferation and induce 
hypertrophy in vivo and in vitro, which did not support the notion of ROS mediating 
mitogenic signaling by Rac1 (Morita et al., 2007). Indeed, we only found a moderate 
reduction of ROS levels in Rac1-deficient chondrocytes. There are many interactions 
between ROS and nitric oxide (NO) (Thomas et al., 2008); for example, NO can react 
rapidly with superoxide and other oxygen species to form nitrite, nitrate, and 
perioxynitrite (collectively called reactive nitrogen species, RNS) (Asou et al., 2002; 
Feelisch, 2008; Ignarro, 1999; Moncada et al., 1991). However, NO or the enzymes 
involved in its synthesis have not been identified as major mediators of Rac1 signaling. 
Therefore we measured NO levels upon deletion of Rac1 in primary chondrocytes and 
indeed found a significant reduction in NO levels. Interestingly, Rac1 deficiency in 
primary chondrocytes resulted in reduced iNOS protein expression but no changes in 
eNOS protein levels. Immunohistochemistry also showed reduced iNOS expression and 
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nitrotyrosine staining, which is an indicator of intracellular NO, in Rac1 null cartilage. 
Therefore we decided to examine the role of iNOS, and subsequently the other two NOS 
genes, in cartilage development. 
           First we performed primary cell culture to investigate the effects of NOS inhibitors 
and NO donors on chondrocytes. We found that inhibition of NOS by LNAME results in 
reduced cell numbers, while NO donors increase chondrocyte numbers. After 6 days of 
tibia organ culture, NOS inhibition resulted in a shortened proliferating zone. In addition, 
we analyzed the rate of cell cycle progression by labeling growth plate chondrocytes in 
the S-phase of the cell cycle with bromo-deoxyuridine (BrdU), demonstrating reduced 
BrdU labeling upon NOS inhibition. Thus we demonstrated that NOS/NO signaling 
regulates chondrocyte proliferation in vitro. In the next step, we started to examine this 
signaling pathway in cartilage growth plate biology in vivo.  
 Using genetically modified mice, we examined the role of iNOS in growth plate 
physiology. The physical appearances of the iNOS KO mice were not distinguishable 
from WT mice. There were no obvious skeletal phenotypes in the KO mice. However, 
close examination of the growth plate showed hypocellularity, especially in the center of 
the growth plate. Counting of proliferating cells showed reduced cell numbers in the KO 
mice. Therefore, we next analyzed cell cycle progression by using BrdU incorporation 
assay which demonstrated reduced labeling in the iNOS KO mice, suggesting slower cell 
proliferation in the KO mice.  
            Although these data established a role of iNOS in regulating chondrocyte 
proliferation, we still did not know whether it mediated Rac1 effects on chondrocyte 
proliferation. We used primary chondrocyte and tibia organ culture models to examine 
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whether addition of exogenous NO could overcome the effects of Rac1 deficiency. 
Addition of SIN-1, a NO donor, rescued the numbers of Rac1-deficient chondrocytes in 
monolayer culture. In parallel, we treated cells with PMA, an inducer of ROS, and 
observed no effects on chondrocyte numbers. Rac1 inhibition resulted in drastic reduction 
of bone growth and shortening of the proliferative zone in the tibia organ culture system. 
The NO donor SNP did not affect bone growth on its own, but completely rescued the 
effects of Rac inhibition on overall tibia growth and the length of the proliferative zone. 
These data demonstrate that restoration of NO levels overcomes the effects of Rac1 
deficiency in the intact growth plate. 
To investigate this signaling pathway further, we examined the mechanism behind 
this regulation of chondrocyte proliferation by examining the expression of cell cycle 
proteins. Cyclin D1 was decreased in the Rac1-deficient chondrocyte culture, and 
treatment with SIN1 but not PMA restored cyclin D1 expression. In agreement with these 
data, expression of the cell-cycle progression protein cyclin D1 was decreased in the 
Rac1 KO mice. We had shown in our laboratory that cyclin D1 expression in 
chondrocytes is repressed by ATF3 (Beier et al., 2001; Beier et al., 1999a; James et al., 
2006). Therefore, we next analyzed the expression of ATF3 in the KO mice and in our 
chondrocyte monolayer culture. SIN-1 treatment reduced ATF3 protein levels both in 
control and Rac1-depleted chondrocytes in cell culture. Additionally, 
immunohistochemistry demonstrated increased numbers of ATF3-positive cells upon loss 
of Rac1 as well as in iNOS KO mice. This suggests premature induction of ATF3 which 
can repress cyclin D1 transcription and result in earlier cell cycle withdrawal. We have 
shown for the first time here that Rac1 activates the iNOS/NO pathway that in turn 
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suppresses ATF3 expression in order to maintain cyclin D1 transcription and chondrocyte 
proliferation. 
             After demonstrating a role of iNOS in chondrocyte proliferation, we next aimed 
to examine whether other NOS genes regulate cartilage development and endochondral 
bone formation. I started by characterizing the phenotype of eNOS-null mice. These mice 
showed decreased viability and increased embryonic death. Examination of the genotype 
distribution of newborn mice revealed that only 14% of pups are homozygote for the 
mutant eNOS allele, and 40% are heterozygote, both numbers lower than the expected 
Mendelian ratios.  These data suggest that loss of eNOS may lead to major abnormities 
during embryonic development and results in increased lethality at the prenatal or 
perinatal stages. Slightly decreased body weight and length were found in eNOS-/- mice at 
birth. Both of these parameters became more pronounced in surviving mutant mice as the 
animals aged (to 6 weeks). However, the phenotypes of the KO mice were variable. 
While the physical appearance of some KO mice was unremarkable in comparison to WT 
mice, some eNOS-/- mice demonstrated a more severe delay in growth and development 
and a significant reduction in size, and some were born with a kinky tail (6 out of 20 KO 
mice from 9 litters). Interestingly, when this phenotype was observed, it always affected 
all KO pups size in that litter.  
            We next examined the skeletal phenotypes of eNOS-deficient mice. There were 
no obvious morphological changes in the mutant skeleton, but neonatal mutant mice 
showed reduced bone length in humeri and tibiae.  Appearance of primary and secondary 
ossification centers was delayed in the eNOS null mice compared with control mice and 
picrosirus-red staining showed fewer and shorter trabecular bones in mutant mice.   
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Because our mutant mice showed skeletal phenotypes, we next analyzed the 
cellular basis of this phenotype. Growth plates from newborn mutant mice displayed 
similar zonal organization as control animals. Measurement of the length of the growth 
plate zones did not show significant difference between genotypes. However, eNOS-/- 
growth plates were hypocellular, especially in the center of the growth plates (similar to 
iNOS null mice). Cell counts in the proliferative zone of the growth plate revealed fewer 
cells per area in mutants, while cell counts in the articular cartilage did not show a 
significant difference between genotypes. I next examined cell proliferation in eNOS-
deficient growth plates. BrdU incorporation assay and immunohistochemical staining for 
PCNA showed a marked reduction in replicating cells in mutant mice.  
           Because our mutant mice are whole body KO mice, we did not know whether the 
skeletal phenotype was due to loss of eNOS gene in cartilage or secondary to defects in 
other organ systems. Therefore, I performed organ culture and primary cell culture in 
vitro. MTT assays demonstrated that mutant chondrocytes increased their numbers more 
slowly than those form control littermates. In addition, tibia organ culture experiments of 
E15.5 eNOS-/- and wild type mice showed that bones from KO mice grew significantly 
less compared to those from control animals. These data suggest that eNOS is required 
for normal chondrocyte proliferation in a cell-autonomous fashion.  
Next I examined cell cycle protein expression in growth plates. 
Immunohistochemical staining of cyclin D1 demonstrated reduced numbers of positive 
cells in mutant mice, while ATF3 expression was increased in eNOS-deficient growth 
plates. Since reduced chondrocyte proliferation is often associated with premature cell 
cycle exit and maturation (Beier, 2005), I next examined the expression of markers of 
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prehypertrophic chondrocytes. Expression of the cell-cycle inhibitor p57 was found 
increased by immunohistochemistry and Western blot in mutant mice. Other 
prehypertrophic and hypertrophic markers, nuclear receptor RORα and Hif-1α, showed a 
similar upregulation in KO mice. Their expression expanded from prehypertrophic zone 
in control animals to the whole prehypertrophic and hypertrophic zone in the growth 
plates of mutant mice. This phenotype is very similar to that we observed in iNOS KO 
mice. This raises the questions whether there are common functions of the different NOS 
genes in cartilage. By using real-time RT-PCR, I found a 3-fold increase of nNOS mRNA 
level in eNOS KO cartilage, while iNOS transcript levels did not change. These data 
suggest that there are compensatory effects between the two constitutively expressed 
NOS genes, nNOS and eNOS.  
Due to the compensatory upregulation of nNOS we found in eNOS KO mice, we 
next decided to investigate the role of nNOS in cartilage development and endochondral 
bone formation. nNOS knockout mice were viable and fertile, and the general appearance 
of stature and gait were unremarkable. The mutant mice showed transient growth 
retardation in young adulthood (2-6-week old).  Other than that, there were no obvious 
skeletal phenotypes. A lack of trabecular structures was seen by picrosirius red staining 
and reduced mineralization of trabecular and cortical bone was demonstrated by Von 
Kossa staining at postnatal day 21. Analyses of the mutant growth plate showed a very 
similar phenotype to iNOS and eNOS null mice. Growth plates from nNOS KO mice 
showed reduced numbers of proliferating and PCNA-positive cells. The mechanisms 
behind this phenotype appeared to be premature induction of ATF3 expression, resulting 
in reduced cyclin D1 expression and chondrocyte proliferation. This suggests that ATF3 
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and cyclin D1 present a common pathway downstream of all three NOS genes in cartilage 
biology.  
Immunohistochemistry also showed increased staining for cleaved (active) 
caspase-3 in cartilage of nNOS KO mice, suggesting increased apoptosis in the mutant 
mice. Expression of the cell-cycle inhibitor p57 and the transcription factors c-Fos and 
RORα was found significantly increased by immunohistochemistry in mutant mice. Real-
time RT-PCR confirmed increased expression of the prehypertrophic and hypertrophic 
markers p57 and Mmp13 in nNOS-deficient cartilage. Interestingly, transcript levels of 
Igf1, which plays an important role in regulating skeletal development and bone 
remodeling (Wang et al., 1992), were also significantly decreased in the mutant mice. 
Moreover, eNOS and iNOS transcript levels were upregulated in nNOS KO mice, further 
confirming the compensatory mechanisms among these NOS enzymes.  
            Collectively, these findings implicate the NOS/NO signaling pathway in 
regulating chondrocyte proliferation, differentiation and apoptosis during endochondral 
bone growth. Table 5.1 summarized the observed phenotypes for all three mutant mouse 
lines. 
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Table 5.1 Summary table of the phenotypes in the three NOS mutant mouse lines. 
 
mice iNOS KO eNOS KO nNOS KO
Bone phenotype Reduced bone length Reduced bone length; 
delayed ossification; 
fewer trabecular bone; 
kinky tail
Reduced bone length; 
fewer trabecular bone 
and reduced 
mineralization
Growth plate Reduced  proliferating 
cell numbers
Reduced  proliferating 
cell numbers
Reduced proliferating 
cell numbers
BrdU
PCNA
Cyclin D1
ATF3
Caspase-3
P57
Rorα
C-Fos
Hif1α
Sox9
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5.2 Contributions and significance  
5.2.1 Contributions to the field of cartilage biology 
         NO has been intensively studied in bone remodeling and arthritis. I showed for the 
first time that NOS/NO pathways regulate chondrocyte proliferation in vivo. Inactivation 
of any NOS gene leads to reduced chondrocyte proliferation, and premature 
prehypertrophic differentiation in growth plates. The significant reduction in bone length 
suggests that these pathways might play an important role in the complex regulation of 
growth plate physiology. NO has been implicated in controlling cell-cycle progression. 
My work identified decreased cycinD1 and increased p57 expression, which could 
explain the reduction in chondrocyte proliferation and bone length. We also identified, 
for the first time, Rac1 as an upstream regulator of iNOS/NO signaling in chondrocytes. 
Similarly, our finding that NOS genes suppress ATF3 expression in chondrocytes is 
novel. This NO ATF3  Cyclin D1 pathway appears to be shared by all three NOS 
genes to regulate chondrocyte proliferation and differentiation (Fig. 5.1). On the other 
hand, NOS/NO signaling delays the onset of chondrocyte maturation.  Premature 
hypertrophic differentiation is also a common feature of all three NOS KO mice and they 
may contribute to the phenotypes observed. Most likely NO effects in chondrocytes are 
differentiation stage- and concentration-dependent. For example, it is plausible to 
speculate that loss of only one NOS protein has different effects as pharmacological 
inhibition of all three.  
            NO signaling has been implied in transducing signals from various extracellular 
stimuli, such as cytokines, chemokines, growth factors and hormones, for the regulation 
of cell growth and metabolism. In addition to ATF3, Sox9 is another candidate  
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downstream target of No signaling. Sox9 is one of the major transcription factors 
regulating early chondrocyte differentiation (Asou et al., 2002; Karsenty and Wagner, 
2002) and was decreased in  eNOS and nNOS KO mice.   
My data also implicate the NO pathway for the first time in the development of 
secondary ossification centers in the epiphyseal cartilage. The formation of SOC had 
been investigated in a number of studies, but not to the same extent as the development of 
primary spongiosa. Therefore, additional insight into this type of regulation will help us 
to understand the similarities and differences between these two components of the 
endochondral bone formation process. My data show that NOS/NO signaling is required 
for the normal onset and progression of secondary ossification. The most important 
findings of my thesis for our understanding of cartilage development are summarized in 
Table 5.1. 
5.2.2 Contribution to the field of NO research 
The role of NO has been intensively studied in inflammatory diseases, tissue 
injury, infection and shock (Mander and Brown, 2004). Although not all details are 
understood, the cytostatic action of NO, when attained at high concentrations from iNOS, 
has been found essential in these processes (Akarasereenont et al., 1994; Swierkosz et al., 
1994; Tomlinson et al., 1994; Vane et al., 1994). However, the stimulatory action of 
lower quantities of NO on cell physiological function, such as cell proliferation and 
migration, has received less attention, although its potential physiological importance is 
already apparent, such as in multiple organ development (Amin et al., 1997; Mander and 
Brown, 2004; Peunova et al., 2001; Reif et al., 2004). Knowledge about the molecular 
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mechanisms and signalling events that are responsible for the enhancement of cell 
proliferation induced by NO is still very limited.  
eNOS-deficient mice showed a significant reduction in neuronal progenitor cell 
proliferation in the dentate gyrus with no difference on apoptotic cell death, suggesting 
that eNOS selectively exerts its effects on the proliferation of progenitor cells. This might 
be mediated by a decrease in VEGF transcripts (Reif et al., 2004). The knockout of the 
nNOS gene results in decreased proliferation of neural precursors with the subsequent 
depletion of immature neurons in the olfactory epithelium of newborn mice, and altered 
organization of glomerular cell layers in the adult olfactory bulb, suggesting a positive 
action of NO on early postnatal development (Chen et al. 2004). NO also enhances cell 
proliferation in neuroepithelial cells of the developing neural tube (Traister et al. 2002; 
Plachta et al. 2003). It has been demonstrated that in lung epithelial and pleural 
mesothelial cells the depletion of endogenous NO by carboxy-PTIO, an NO scavenger 
compound, stops cell proliferation by arresting the cell cycle (Janssen et al. 1998).  
In the cardiovascular system and heart development, eNOS KO mice are 
hypertensive and lack NO-mediated, endothelium-dependent vasodilation, have 
suppressed smooth muscle cell proliferation and display a negative inotropic effect (Sato 
et al., 2000). In a human bone marrow-derived mesenchymal stem cell culture (HBMSC), 
nitroglycerin (0.1–10 μM) led to a dose-dependent increase in cell proliferation and 
osteoblastic differentiation of HBMSC (Aguirre et al., 2001). Two NO donors, sodium 
nitroprusside (SNP) and S-nitroso-N-acetylpenicillamine (SNAP), stimulated an increase 
in myoblast cell number over a range (1-10 pM) of donor concentrations (Ulibarri et al., 
1999). 
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Controversy exists about the antiproliferative role of NO in smooth muscle cells, 
Drosophila and Xenopus development and a kidney cell line. One study showed that NO 
is involved in controlling the size of body structures as an antiproliferative agent during 
Drosophila development (Kuzin et al., 1996). And NO is an essential negative regulator 
of cell proliferation in the Xenopus brain (Peunova et al., 2001). Constitutive expression 
of nNOS plays an antiproliferative role in human airway smooth muscle cells (Amin et 
al., 1997). eNOS gene transfer inhibited cellular proliferation in a human embryonic 
kidney cell line (Maeda et al., 2000).  
Collectively, the regulatory action of NO on cell proliferation is exerted in a 
biphasic mode, enhancing and inhibiting the progression of the proliferative process 
depending on the actual concentration of NO encountered by the cell and likely also the 
specific cell type. My data will contribute to elucidate the physiological role of NO in 
chondrocyte proliferation and also provide the mechanisms underlying this regulation.  
The action of NO stimulating the proliferation of tumor cells has also become an 
important pathophysiological issue (Yoon et al., 2004). The studies concerning the action 
of NO on cancerous cells could be significant to better understand the molecular 
mechanisms underlying this pathological process and its possible therapeutic control. It is 
postulated that the NOS/NO pathway may be implicated in cellular proliferation and 
DNA or RNA synthesis of cancer cells, apart from promoting tumor angiogenesis (Shang 
et al., 2006) as well as its role in regulation in cell cycle progression in cancer cells (Holt, 
2000).   
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5.2.3 Contribution to the understanding and development of therapeutic strategies 
in skeletal diseases 
Achondroplasia, caused by activating mutations in the FGFR3 gene, is the most 
common genetic form of dwarfism (Yasoda et al., 2004; Zelzer and Olsen, 2003). 
Currently, there is no treatment for achondroplasia other than distraction osteogenesis. In 
a mouse model of achondroplasia, systemic administration of CNP or cartilage-specific 
overexpression of CNP in transgenic mice was shown to be very effective in promoting 
bone growth (Yasoda et al., 2009; Yasoda et al., 2004). No side effects, including tumor 
growth, were observed after intravenous administration of synthetic form of CNP, CNP-
22 (Yasoda et al., 2009). CNP is a promising candidate for treatment of achondroplasia 
and potentially other skeletal dysplasias, but as a peptide it is relatively expensive to 
generate and difficult to deliver to target cells in non-vascularized cartilage. NO and CNP 
converge on the secondary messenger cGMP and thereby activate cGKII in cartilage. As 
my data suggest, NOS/NO promote chondrocyte proliferation in cartilage. This may 
imply a potential therapeutic target for treatment of achondroplasia, and possibly other 
chondrodysplasias. Similarly such approaches might be useful in the treatment of other 
skeletal diseases including trauma and osteoarthritis. 
More generally, skeletal development is a well controlled, complex process, and 
improved understanding of this process will help us comprehend how disturbances can 
compromise the function of the entire system and how we can counteract such 
disturbances.  
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5.3 Limitations of research project and future directions 
5.3.1 Limitations of interpretation 
         Reduced chondrocyte numbers in our mutant mice could also be due, in part, to 
increased apoptosis (in addition to reduced proliferation). Although the observed 
apoptosis, shown by cleaved caspase-3, was mainly located in terminal differentiated 
hypertrophic chondrocytes, there is a chance that apoptosis or other forms of cell death 
also play a role to reduce chondrocyte numbers. Therefore the decreased chondrocyte cell 
numbers in KO mice could be a combination of reduced proliferation and increased 
apoptosis. It would be useful to examine growth plates at different developmental stages 
to elucidate this question. High concentrations of NO have long been linked to 
chondrocyte apoptosis (Moncada et al., 1991), while the low level of NO from cNOS 
(eNOS and nNOS) could be protective in chondrocyte survival. As we did not study this 
effect in iNOS and eNOS KO mice, it would be useful to examine chondrocyte apoptosis 
in these KO mice.  
         The regulation of Sox9 expression by the NOS/NO signaling pathway in 
chondrocytes is very interesting and potentially important, but I cannot conclude whether 
this is due to direct regulation by NOS/NO or secondary to other events. In addition to 
our results, Sox9 nuclear translocation has been found to be regulated by cGKII in rat 
chondrocytes (Chikuda et al., 2004), suggesting that regulation of Sox9 by 
NO/cGMP/cGKII is complex and occurs at multiple levels. Further analysis of these 
relationships is required for a more complete understanding of the downstream events of 
NO signaling during cartilage development. 
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         We demonstrated in this project that NO suppresses the expression of ATF3 which 
we expect to be responsible for reduced chondrocyte proliferation. However, I cannot 
determine for sure whether suppression of ATF3 by NO is functionally important in this 
context. Ultimately, one will need to look at ATF3 KO mice and potentially double KO 
with NOS to address this question.  Although we identified the Rac1 as an upstream 
factor to stimulate iNOS expression and NO synthesis, I do not have data to examine 
whether they are under direct regulation or there are intermediate pathways connecting 
Rac1 to iNOS. Similar questions also exist regarding the inhibitory effects of NOS on 
ATF3 expression. The signaling pathways connecting NOS to ATF3 regulation need to 
be elucidated. Finally, the expression of cell cycle inhibitor p57 was clearly increased in 
all three NOS KO mice. But it is not clear whether upregulation of p57 and other 
prehypertrophic markers is secondary to premature cell cycle exit or independently 
regulated by NOS/NO. Addressing these questions will lead to a better understanding of 
cartilage biology.  
5.3.2 Limitations of the experimental models 
         My results show that all three NOS share a common pathway in regulating 
chondrocyte proliferation and differentiation. However, phenotypes are most severe in 
eNOS KO mice, and minor differences between the three strains were seen (Table 5.1). 
Further investigation of any double or triple NOS KO mice are required to address 
redundancy and functional overlap between the three NOS genes. We have attempted 
such crossings, but were not successful in obtaining double KO mice. The use of 
conditional alleles that allow cartilage-specific deletion (and thus limit other phenotypes 
that could contribute to lethality) would be one approach to overcome this limitation.  
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          Our mutant strains are conventional KO mice where the NOS genes have been 
deleted in each cell of the body. Therefore, some of the observed phenotypes could be 
due to primary defects in other cell types (e.g. the vasculature or endocrine organs). The 
similarity of our results in organ cultures and KO mice supports that the observed effects 
are due to direct effects of NO signaling in chondrocytes. However, ideally these results 
should be confirmed by in vivo experiments. The generation of conditional mutants using 
the Cre-lox system in combination with a cartilage-specific Cre driver line would be the 
best approach to address this question. 
          Another major concern of this project is the variable phenotype of the KO mice, 
especially in eNOS KO mice.  Some KO mice (whole litters) showed a severe reduction 
in size compared to other KO mice. Based on this observation, we increased the sample 
size of the KO mice to at least eight litters to reach statistical difference.  Growth of these 
KO mice is measured by body length and weight at different stages from newborn to six 
weeks to compare the difference in skeletal growth.  It would be very useful to include 
prenatal stages and expand this study to a longer period of time. Moreover, some of the 
variance could be due to eNOS effects in other tissues; once again these could be 
overcome by the generation of cartilage-specific KO mice. 
          My data suggest that three NOS KO mice share a common signaling pathway to 
suppress cyclin D1 and inhibit chondrocyte proliferation. However, each individual NOS 
may respond to different upstream regulators in controlling chondrocyte fate. For 
example, we identified Rac 1 as activator of iNOS but not eNOS expression in cartilage. 
We do not know now what are the other upstream signaling to regulate eNOS and nNOS 
expression in cartilage.  Interestingly, we found compensatory mechanisms among these 
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three NOS genes in cartilage; unregulated nNOS transcript levels in eNOS-null cartilage; 
and upregulated eNOS and iNOS mRNA in nNOS KO mice. This could explain the 
variability of the NOS KO phenotypes and the catch up growth of the KO mice after 
transient growth retardation at young age.   
          In this research project, we used primary chondrocyte monolayer culture and tibia 
explant culture. The monolayer culture system is an economical and technically simple 
model, allowing the culture of a high number of chondrocytes. Primary chondrocytes 
were isolated from long bone of E15.5 tibiae. At this stage mineralization and vascular 
invasion has just been initiated and a mixture of cell types is probably present (e.g. cells 
from primary spongiosa, and perichondrial cells could also be present in the monolayer 
cultures). However, cell types other than chondrocytes only represent a small percentage 
of the entire cell population. Nevertheless, because of the heterogeneous type of cell 
culture we cannot exclude that some of the observed NO effects are also due to the 
interference with other cell populations. Moreover, in primary monolayer culture, loss of 
chondrocyte phenotype was reported after a long period time of incubation. We limited 
the culture time to 48 hours to minimize the effects of this limitation and have not 
observed a changes in chondrocyte morphology. Nevertheless, three-dimensional cultures 
systems such as micromass cultures (Stanton et al., 2003; Woods et al., 2007b) would be 
one way to overcome this limitation. 
          Tibia explant culture was employed in this project for further validation the 
observed effects in vitro. The intact tibia is cultured in serum-free medium and 
pharmacological inhibitors can be used to alter signaling pathways in the correct three-
dimensional context. Cell-cell and cell-matrix interactions are preserved in this system 
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and the effects of inhibitors or growth factors can be observed in a growth plate zone-
specific manner. On the other hand, the organ culture system removes bone from other 
organ systems, such as endocrine and biomechanical environments, and allows us to 
study the effects of a single growth factor without influence of other organ systems.  
Using this system, I was able to observe specific effects in certain chondrocyte 
subpopulations, which would be impossible in a cell culture model.  
5.3.3 Limitations of techniques and reagents 
         Using immunohistochemistry as a main technique in this project has certain 
disadvantages, such as the potential for nonspecific signals and difficulties in quantifying 
signals. Typically, sections of KO mice or organ culture from at least six independent 
trials, and representative images from each trials were analyzed to draw conclusions 
based on the immunostaining results (Stanton et al., 2007). Western blotting or RT-PCR 
was also conducted to further verify the results of protein or gene expression in 
chondrocytes in some key experiments. Controls included the omission of the primary 
antibody and, in some cases, use of tissues from KO mice for the protein of interest (e.g. 
the different NOS KO lines). Furthermore, expression patterns for proteins examined 
corresponded to those described in the literature. Nevertheless, we have to acknowledge 
the potential for lack of specificity of antibodies in IHC.  
         Another technical limitation in this project is that I cannot measure NO levels in 
vivo. NO is known to be formed in small amounts in vivo and is rapidly transformed by 
interaction with oxygen (Hashimoto et al., 1999), making measurement difficult. 
However, use of the fluorescent dye (DAF-FM) provides a sensitive and accurate method 
to analyze the relative quantification of NO production from chondrocytes in culture, but 
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it cannot give the absolute concentration of NO levels. For in vivo studies, we had to rely 
on the use of an antibody for nitrotyrosine as a substitute for measuring NO levels 
indirectly. 
          Another limitation to our study is the reliance on a pharmacological inhibitor, 
LNAME, to analyze the role of the NOS/NO in chondrocyte physiology. LNAME 
demonstrates potent inhibition of all three NOS proteins (Hashimoto et al., 2006); 
however, there are differences in its potency on the different enzymes, (IC50 of eNOS, 
iNOS and nNOS are 0.7, 3.9 and 0.65 μM respectively). By using a relatively high 
concentration, the inhibition was reported to be effective for all three NOS isoforms 
(Hashimoto et al., 2005). We used different concentrations of NOS inhibitors and 
measured NO production in parallel to test its effects and optimize the concentration 
under our culture conditions.  
           NO donors gave us the possibility to observe the effects of NO on chondrocyte 
without transfection. However, SNAP is a compound that is known to have peroxide 
effect to cause cell membrane lipid peroxidation (Kim et al., 2005). Therefore use of 
another NO donor helped us to validate the results. NOC-18 (DETA-NO) is a long-
lasting diazeniumdiolate compound with a half-life of 27 hours (Chikanza et al., 2000). 
SIN1 is an inducer of NO and ROS. For the NO donors employed in this project, their 
effects on cell proliferation, NO and ROS levels were measured before we used them in 
these experiments. All donors had similar effects on the measured parameters. 
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5.4 Conclusions      
In conclusion, this research project has shown that the NOS/NO signaling 
pathway plays important and physiological roles in multiple steps of endochondral bone 
formation, in particular in the control of chondrocyte proliferation. My thesis has 
identified several molecular mechanisms involved, such as NO suppression of ATF3 
expression and subsequent effects on the chondrocyte cell cycle. These studies contribute 
to a better understanding of physiological bone growth and may ultimately result in 
improved therapeutic strategies for skeletal diseases.  
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